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Affibody is a new class of engineered affinity protein, and has great properties com-
pared with antibody. The aim of the project is to construct a new generation Affibody 
molecule phage library in which the bound phages are cleaved by trypsin in the selec-
tions against target molecules. First, a new phagemid vector pAffi-100-Tryp was creat-
ed for new library preparation. Second, in comparative test selections with low-pH acid 
and trypsin cleavage elution, the functional display was ensured. Then, a new genera-
tion Affibody molecule library was constructed for highly stringent binder selections. 
The size of the library is approximately 4.7×10
9
 cfu.  In the selection against rhEphrin-
B3, the bound phages were able to be cleaved by trypsin, and re-infect. After four 
rounds selection, candidate binders were selected for subcloning. According to the se-
quencing results, there were similar patterns among those candidate binders. Also, only 
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LIST OF ABBREVIATIONS 
 
ABD  Albumin Binding Domain 
Amp  Ampicillin 
BSA  Albumin from bovine serum 
cfu  Colony-forming units 
ELISA  Enzyme-linked immunesorbent assay  
e-o-e   End-over-end 
Ig   Immunoglobulin 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
Km  Kanamycin 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline with 1% (v/v) Tween 
PCR  Polymerase chain reaction 
PEG  Polyethylene glycol 6000  
pfu  Plaque-forming units 
RT  Room temperature 
scFv  Single-Chain Variable-Fragment 
ssDNA Single stranded DNA 
Tet  Tetracycline 
TSB  Tryptic Soy Broth 





Antibodies are still the most successful affinity proteins for life science applications, 
which is due to their capability to be virtually isolated and bind targets with high affini-
ty and specificity. The most popular used antibody is IgG molecule. However, it has 
poor heat stability, also the manufacturing process is comparatively difficult and expen-
sive (Löfblom et al., 2010).  
Affibody is recognized as a new class of engineered affinity protein, which is 
derived from the B domain of staphylococcal protein A (SPA). When compared with 
antibodies, Affibody molecules consist of alpha helices and lack disulfide bridges. In 
addition, Affibody owns higher physical and chemical stability. Affibody can be engi-
neered and bind to a large number of target proteins or peptides with high affinity. 
There are 13 amino acid positions which can be randomly mutated in helix1 and helix2 
of B domain to construct an Affibody library (Nygren, 2008). A specific Affibody is 
able to be obtained after affinity panning (Russel et al., 2004). It is possible to co-
express Affibody with reporter molecules such as fluorescent protein (Engfeldt et al., 
2005). Affibody has been used in detection, separation, and purification of target pro-
teins (Löfblom et al., 2010).  
There are several commonly used Affibody selection systems: phage display, 
cell surface display, and ribosome display (Gunneriusson et al., 1999; Friedman et al., 
2007; Grimm et al., 2011). These different selection systems are associated with differ-
ent aspects of protein expression and presentation. Phage display technology is the most 
widely used (Grimm, 2011). This technology is based on the filamentous bacteriophag-
es with the ability to infect Escherichia coli cells. The foundation of this technology is 
the physical linkage between phenotype and genotype. It is possible to generate relative-
ly large libraries and no need of costly reagents and equipment (Russel et al., 2004).  
The aim of the project is to construct a new generation Affibody molecule li-
brary for highly stringent binder selections. The project is performed in four stages: 1) 
phagemid vector engineering, 2) comparative test selections with low pH acid and 
Trypsin, 3) construction of large naïve Affibody library with phagemid pAffi-100-Tryp, 
and 4) selection to rhEphrin-B3. This project is supervised by Ph.D student Feifan Yu in 
Prof. Per-Åke Nygren research group: “Affinity Protein Engineering” in Royal Institute 






2.1 Protein engineering  
2.1.1 Brief history 
Proteins are polymeric compounds made up of amino acids. Amino acids are linked 
together via peptide bonds between the α-carboxyl groups and the α-amino groups. 
Generally, proteins refer to the structures containing 50 to 1000 amino acids per chain, 
while others possessing less than 50 amino acids are called peptides or polypeptides. 
Proteins play key roles in the process of life, and have diverse functions in all biological 
systems.  For example, some proteins act as enzymes and catalyze specific biochemical 
reactions. Antibodies, serving as defensive proteins, can identify and bind to specific 
foreign molecules. Structural proteins support cell structure. Actin and myosin are con-
tractile proteins which are fundamental for movement in muscles. Signal proteins are 
associated in regulation of cell metabolism. Transport protein hemoglobin transports 
oxygen (Ewait et al., 2014).  
Berzelius was the first person to coin the term “protein” in 1838.  He considered 
this kind of material was the primitive substance of animal nutrition prepared by plants 
for the herbivores (Hartley, 1951). In 1926, Sumner revealed that urease is a protein by 
examining the crystallized form. He was the first one to demonstrate most enzymes are 
proteins, and got the Nobel Prize in chemistry in 1946 (Karplus et al., 1997). The first 
sequenced protein is insulin which contains 51 amino acids. Sanger showed the amino 
acid sequence of insulin in 1951, and was rewarded the Nobel Prize in chemistry in 
1958 (Sanger and Tuppy, 1951). Also in the year of 1958, the protein structure of myo-
globin and oxy-myoglobin were demonstrated by X-ray crystallography (Kendrew et 
al., 1958; Perutz et al., 1960). The work was performed by Kendrew and Perutz, and 
they shared the Nobel Prize in chemistry in 1962.  
Before 1980s, the only way to engineer protein was chemical modification with 
which nucleophilic amino acid side chains were modified with acylating or alkylating 
chemicals. In 1982, the tyrosyl-tRNA synthetase was the first enzyme studied in protein 
engineering. The tyrosyl-tRNA synthetase from Bacillus stearothermophilus was engi-
neered by systematic site-directed mutagenesis to substitute single amino acid residues. 
The result showed important experimental evidence about the enzyme catalysis theories 
(Greg et al., 1982). This method enabled scientists to improve or alter existing protein 




However, rational approaches have limitations to predict the outcome of site-
directed mutations. In order to overcome the restrictions, so-called library-based ap-
proaches were pointed out to engineer proteins (Griffiths et al., 1994). Protein diversity 
can be generated via PCR. Mutations are randomly produced during amplification cy-
cles with the diversity introduction in nucleic acids. Random mutants may be inserted 
into any piece of DNA by error prone PCR (Cirino et al., 2003). The fidelity of the Taq 
DNA polymerase is modulated by altering the composition of the reaction buffer. 
Therefore, mistakes in base paring take place which results in the introduction of errors 
in the newly synthesized complementary DNA strand. Another method is to use cassette 
mutagenesis (Virnekas et al., 1994). Mixtures of oligonucleotides are designed, synthe-
sized, and then inserted into a plasmid. Both of the plasmid and the oligonucleotide are 
cleaved by the same restriction enzymes. The oligonucleotides containing the mutation 
are ligated complementarily into plasmid. This method enables almost 100% efficiency 
to generate mutants.   
The possibility to engineer protein emerged with the rapid development of vari-
ous studies on proteins. Protein engineering refers to the process of developing useful or 
valuable proteins. The generally used strategies can be classified into rational protein 
design and directed evolution (Grimm, 2007). In rational protein design, detailed 
knowledge of the structure and function of the protein is necessary to make desired 
changes. Site-directed mutagenesis is a typical rational design. However, it is extremely 
challenging to predict the effects of various mutations. Directed evolution mimics natu-
ral selection processes in a test-tube. Random mutagenesis is expressed in protein. The 
variants specific for a certain target are picked out in a selection system. Then, further 
rounds of mutation and re-selection are applied. Phage display is a very successful se-
lection system. In 1985, Smith first displayed peptides on f1 filamentous phage. Phage 
display is based on the linkage of genotype and phenotype (Smith, 1985). It is a power-
ful system for protein selection. Afterwards, other selection systems such as bacterial 
display, ribosome display, and mRNA display were created (Gunneriusson et al., 1999; 
Friedman et al., 2007; Grimm et al., 2011).  
One important aim in protein engineering is to modify, create or inhibit protein-
protein interaction. Affibodies have been designed to recognize pathogenic and foreign 
substances, and used as high-specificity reagents. Antibodies own the ability to bind 
specifically to their target molecule antigen. There are five different subclasses of anti-
body: IgG, IgM, IgA, IgE, and IgD. IgG is the most widely used antibody, and it con-
sists of two identical heavy chains and two identical light chains with about 150 kDa 
molecular mass. Antibodies can be produced by immunizing animals with an antigen. 
Polyclonal antibodies with amino acid sequences are obtained, and they can recognize 
different epitopes on the same antigen. In 1975, Köhler and Milstein first introduced 
monoclonal antibody based on hybridoma technology (Köhler and Milstein, 1975). 
Monoclonal antibodies are produced by the fusion of antibody-producing B-cell and 
myeloma cancer cell. They only bind one epitope, and perform excellently as affinity 




cross-links. Various problems have been encountered which limit the development of 
some researches. New engineered antibody fragments, such as Fab fragment and scFv, 
are developed to overcome the restrictions. They have reduced size but still retain anti-
gen binding specificity (Grönwall, 2008).  
Alternative non-immunoglobulin affinity proteins have also been developed 
without the limitations of antibodies. New proteins that designed for novel binding 
functionality typically lack disulfide cross-links, have small size, good stability and sol-
ubility, and are easy to produce in large quantities in E. coli. The novel designed pro-
teins generally have globular protein scaffolds or repeat protein scaffolds. Many globu-
lar protein scaffolds including monobodies, Affibody, PDZ, and Srchomology3 (SH3) 
as well as WW domains have been created to different binding specificities. Further-
more, some repeat proteins scaffolds are used in protein engineering, such as tetratrico-
peptide repeat (TPR), leucien-rich repeat (LRR), and ankyrin repeat (ANK) (Sawyer et 
al., 2013).   
2.1.2 Protein traits 
2.1.2.1 Affinity and selectivity 
Affinity and selectivity give the description of the protein binding characteristics. Bind-
ing to another molecule is one simple way for proteins to perform their function. The 
strength with which any two molecules bind to each other shows the affinity. The units 
of equilibrium constant (K) for a reaction where two molecules (A and B) bind to each 
other are liters/mole. K is calculated from the concentrations of A and B, as well as the 




                                                        
where [A] and [B] are the individual concentrations of molecule A and B, and [AB] is 
the concentration of complex AB at equilibrium. K is also known as association or af-
finity constant Ka.  
The equilibrium is maintained by a balance between the opposing reactions: dis-
sociation and association, which is described as: 
  
   
    
                                                            
where koff is the dissociation constant, and kon is the association constant. In order to get 
high affinities, both fast association constant     and slow dissociation constant koff are 
needed. At equilibrium, the association rate is equal to the dissociation rate: 
   [ ][ ]      [  ]                                    
where    [ ][ ] gives the association rate, and     [  ] means the dissociation rate. 





                                                 
where ΔG is in kilocalories and T is the absolute temperature in Kelvins. It is noted that 
for every 1.14 kcal/mole decrease in free energy the equilibrium constant increases by a 
factor of 10 at 37˚C (Alberts et al., 2008) .  
Selectivity is another import trait for protein generated for binding other mole-
cules. It is the ability of a molecule to discriminate a particular analyte from a complex 
mixture without interference. Both of affinity and selectivity of a protein can be im-
proved. For example, a variant of Herceptin was isolated with the ability to interact with 
human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth fac-
tor (VEGF) at the antigen binding site (Bostrom et al., 2009). Moreover, a conventional 
IgG molecule MEHD7945A was generated to bind two epitopes human epidermal 
growth factor receptor 3 (HER3) and human epidermal growth factor receptor (EGFR) 
with high affinity. It was demonstrated to inhibit both EGFR- and HER3 mediated sig-
naling in vitro and in vivo (Schaefer et al., 2011).  
Equilibrium dissociation constant Kd (1/ Ka) is frequently used to evaluate the 
affinity of a protein. In order to measure Kd, protein A with a fixed concentration is ti-
trated with its ligand B in various concentrations. The bound complex AB gives a signal 
which correlates with its concentration. This approach has been applied in many tech-
niques, such as isothermal titration calorimetry (ITC), enzyme-linked immunosorbent 
assay (ELISA) (Bobrovnik, 2003; Freyer and Lewis, 2008). However, there are some 
limitations of these techniques. The kinetic parameters kon and koff are not measurable, 
and it may take longer time to reach equilibrium in high affinity interactions.  
Biospecific interaction analysis (BIA) is an optical technology which has been 
developed to study the binding properties of biomolecules. Biacore is a commercial 
optical biosensor system, and the detection principle is based on surface plasmon reso-
nance (SPR). It enables to detect and measure the kinetic parameters of the interaction 
between two or more molecules. One advantage of this technology is that non-label of 
the molecules to detect is required. It also brings the possibility to measure the rate con-
stants kon and koff to calculate Kd without the need to reach equilibrium. Surface plas-
mons are one kind electromagnetic wave, and they arise when the entering photons in-
teract with oscillations of electron plasma in the metal. The energy of the incident pho-
tons must exactly match the energy of the plasmon. Total internal reflection of light on 
the metallic surface leads to the excitation of plasmons, where energy from incident 
photons is effectively transferred to plasmons. The most conventional SPR sensor is in 
Kretschmann configuration (Figure 1). The excitation of plasmon depends on the wave-
length of the light λ, angle of incidence θ, and thickness of the metal film, as well as 
dielectric function ε of the metal, prism and medium adjacent to the metal film (Buerk, 
1993; Roh et al., 2011).  
In practical, one component of ligand A or protein B is immobilized on the gold 
surface. When the other component flows over, proteins interaction occurs. The ab-
sorbed molecules cause a proportional increase in refractive index, which leads to a shift 
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where A represents the ligand and B the analyte protein. kon is the association constant, 
and koff is the dissociation constant. t is the reaction time. After a certain time, the sys-
tem gets a stable state when    [ ][ ] equals     [  ]. The equilibrium constant K is 
described in Eq.(2).Then, buffer without analyte flows the fluidic channel, and a desorp-
tion of the ligand occurs. In this phase, the kinetic equation is quite similar to the one in 
association. At last, a pulse of dissociating agent is injected to remove the remaining 
ligands and regenerate the free receptors (Figure 2) (Cooper, 2002; Berthier and Silber-
zan, 2010). 
 
Figure 1. SPR sensor in Kretschmann configuration. In Kretschmann method, a prism coupler is attached 
with a thin metal film (Derived from Roh et al., 2011). Targets protein flows over the immobilized lig-
ands in fluidic channel. P-Polarized light enters with the incident angle θ. np is the refractive index of the 
dielectric prism. βspp is the excited SPP (surface plasmon polariton) propagation constant.   
 
 
Figure 2. Binding kinetics in a typical binding cycle obtained by SPR (Derived from Cooper, 2002). 
Ligands (A) are immobilized on the sensor surface. With the injection of analytes (B), the resonance 
signal increases due to the formation of ligand-analyte complexes (AB). After the association phase, ana-
lytes solution is replaced by buffer. The dissociation of the complexes (AB) causes decrease in response. 





Stability is the state of protein with net balance of forces. Protein stability normally re-
fers to the physical thermodynamic stability. As for chemical stability, it involves loss 
of integrity caused by bond cleavage. Generally, the degradation processes take place in 
two steps. The first step is reversible which corresponds to the unfolding process, and 
the second step is irreversible which leads to the degradation of the unfolded protein 
molecule:  
                               
where N represents the native proteins, U the unfolded state and F the final state. The 
stability of a protein refers to the difference in free energy between the native and un-
folded state. K is defined as the equilibrium constant, it is the ratio of forward reaction 
    rate constant and reverse reaction     rate constant. It suggests the unfolding 
state of proteins is transient (Lumry and Eyring, 1954; Cueto et al., 2003). 
Extreme pH can lead to denaturation of some proteins. Electrostatic repulsion 
due to the titration of all the ionizing groups overcomes the attractive forces and results 
in unfolding of the protein. Denaturants, such as urea and guanidinium hydrochloride in 
high concentrations, can also affect the protein stability, and may cause complete un-
folding of the protein (Grimm, 2007).  
Temperature-mediated denaturation is related to the disruption of hydrogen 
bonding and the increase of hydrophobicity. Differential scanning calorimetry (DSC) is 
one frequently used method to analyze stability. DSC connects temperature with specif-
ic physical properties of substances, and it is the only method enables a direct determi-
nation of the enthalpy in the process of interest. The calorimetric changes in proteins are 
measured as a function of temperature. There is a difference between the heat capacity 
of the sample (Cp) and the one of reference buffer. Therefore, more energy is required 
for the sample to the same temperature as the reference. The additional energy is pro-
portional to the excess heat capacity. Melting temperature TM can be directly measured 
by DSC, it shows the temperature at which half of the protein molecules are in the na-
tive state and the other in the unfolded state. Cp of protein molecules is not constant in 
the process, and it gets increased for denaturation. The heat capacity Cp in unfolded 
state is greater than in folded state. The change of Cp is considered due to the disruption 
of the forces stabilizing native protein structure. Both equilibrium and kinetic of protein 
thermal stability can be quantified by DSC. DSC has the potential to become a universal 
method to study termal denaturation, because it does not rely on changes in spectro-
scopic signal (Grill et al., 2010; Johnson, 2013).  
Any technique which is able to distinguish proteins between unfolded state and 
folded state can be used to analyze stability. Another commonly used method is circular 
dichroism (CD). CD is based on the measurement of a very small different refractive 
indexes, when left and right circularly polarized light are simultaneously pass through 
the solution containing protein samples. CD spectra ranging from 160 to 250nm are 




from 250 to 350nm are applied detect the side chain tertiary structures of proteins. In the 
thermal stability detection by CD, a single wavelength is chosen to monitor a certain 
specific structure. The signal at this wavelength is monitored with constant increasing 
temperature. An ellipticity value in degree is given corresponding to a certain tempera-
ture. In a typical graph of CD measurement, the midpoint of the transition shows the 
melting temperature TM, and the width is related to the enthalpy of unfolding (Berova et 
al., 2000; Kelly et al., 2005).  
2.1.2.3 Enzyme activity 
Probably, catalysis is the most important of all the functions of proteins. Enzymes are 
able to increase a reaction rate by a factor of up to 10
20
 over uncatalyzed reactions. In 
the Michaelis-Meten model (single substrate enzyme catalyzed reaction), the initial 
formation rate of product can be expressed as: 
  
    [ ] [ ]
   [ ]
                       
where V is the initial rate of reaction, [S] represents the substrate concentration,      is 
the turnover number,    is called Michaelis constant, and [ ]  gives the total concen-
tration of enzyme. The turnover number       is defined as the number of moles of sub-
strate that react to form product per mole of enzyme per unit time, and it gives a dra-
matic illustration of the efficiency of enzymatic catalysis. If all the enzymes are saturat-
ed with substrate and the reaction occurs at the maximum rate, the formula can be writ-
ten as: 
  
    [ ]
   [ ]
                             
where      is the maximum theoretical rate at infinite substrate concentration. When 
the rate of the reaction V is half its maximum value      , the substrate concentration 
[S] is equal to the Michaelis constant    (Campbell et al., 2012).  
An enzyme’s activity refers to the general catalytic properties of the enzyme. 
The factors (e.g. substrate concentration, pH, and temperature) can affect the activity of 
an enzyme. In Michaelis-Menten formula, the measured rate varies more rapidly as the 
substrate concentration decreases. The reaction occurs with first-order kinetics, where 
the reaction rate depends on concentration of substrate. However, zero-order kinetics in 
the reaction is observed, if the enzyme is saturated with higher substrate concentration 
(well beyond 10    ). It means the reaction rate dos not depend on concentration of 
substrate. Moreover, there are some enzymes known as allosteric, it shows a sigmoid 
shape of the rate variation with substrate concentration. Enzymes are active only within 
a limited range of pH. The maximum activity is obtained at an optimum pH value. The 
pH effect test is generally performed at high substrate concentration, because    might 
cause a change of initial reaction rate V. Generally, a pH value is chosen close to the 
optimum, also enables the operation of all other components in the assay. Temperature 




C growth. However, the enzyme protein denatures at high temperature, and lead to the 
decrease of product formation (Scopes, 2002).  
Enzyme activity measurement is normally performed in vitro under defined 
conditions. In order to measure the activity of an enzyme, either how much product is 
formed over a given time or how much substrate has been utilized should be measured. 
There are two normally used approaches: stopped assay, and continuous assay. In stop 
assays, the reaction is stopped after a fixed time, and the amount of formed product is 
measured. The stop of the reaction is achieved by the denaturation of the enzyme. For 
example, strong acid, alkali or detergents are used, as well as irreversible inhibitors. 
Also, the addition of complexing agent such as EDTA removing the essential metal ions 
for activity can stop the reaction. Sometime, a separation step is required to separate 
remained substrate from product. The separation methods include chromatographic, 
solubility and partition procedures. If a selective method is available to distinguish be-
tween substrate and product, the separation step is not essential. The reaction is not dis-
turbed in continuous assays and it is possible to check the results immediately. The 
amount of formed product is detected by measuring the change of some possible physi-
cal parameters when the reaction occurs, such as UV/vis absorption fluorescence emis-
sion or phosphorescence. For an instance, hydrogen peroxide (H2O2) and gluconate are 
the products by incubating glucose with glucose oxidase. With the help of peroxidase, 
H2O2 oxidizes a reduced dye and causes a color change (Scopes, 2002; Grimm, 2007).  
2.2 Protein selection systems 
2.2.1 Phage display 
Bacteriophages are the viruses that can infect bacteria, and harmless to humans. There 
are countless types of bacteriophage (phage). Phage display is regarded as a means to 
display foreign proteins on filamentous bacteriophage. Filamentous bacteriophages con-
tain a circular ssDNA genome which packaged into long filaments. These phages are 
non-lytic phages. Therefore, they are secreted into the environment without killing the 
host. Filamentous bacteriophages are specific for the Gram-negative bacteria E. coli 
having F-pili. The Ff family of filamentous bacteriophage includes f1, fd, and M13, 
which can infect F
+
 E. coli through binding with their F pili (Bratkovič, 2009). In the 
life cycle of filamentous bacteriophages, they first infect the E. coli cells with F pili. 
After the infection, the ssDNA of phage is inserted into the cell and replicated into 
dsDNA. The genes encoding for the capsid proteins are transcribed and translated. New 
phages are assembled with new ssDNA and capsid proteins in the bacterial envelope, 
and hundreds of phages are released (Barbas et al., 2004).  
Phage display is used to express foreign (poly)peptides on the surface of phage 
particle. This is achieved by splicing a gene encoding into a gene encoding a capsid 
structural protein. It makes the linkage of genotype and phenotype of select recombinant 




was reported that a foreign DNA fragment was inserted into the phage genome, and 
phage particles displaying foreign polypeptide as a fusion to the coat protein was yield-
ed (Smith, 1985).  
Foreign peptides and proteins can be displayed on the phage surface by fusing 
the gene to the phage ssDNA. M13 is the most commonly used filamentous bacterio-
phage. The ssDNA of M13 is encapsulated with about 2700 copies of major coat protein 
pVIII. There are five copies of pVII and pIX in one end, and five copies of pIII and pVI 
in the other end. The foreign proteins are displayed either on pIII or on pVIII. The basic 
principles of pIII and pVIII are quite similar. The perhaps reason for using either of the 
two capsid protein as the display platform is the display valency; peptides fused to pIII 
can be displayed in up to five copies per virion,  while it is possible to present hundreds 
or thousands of peptides fused to pVIII in single phage (Bratkovič, 2009).  
The most commonly used coat protein is pIII for display. There are three do-
mains in g3p: N1, N2, and CT (C terminal) (Figure3).  Each domain is separated by 
glycine-rich linker regions (Gly1 and Gly2).  The N1 and N2 regions interact with each 
other intramolecularly. During the infection process, the N2 domain interacts with the F 
pilus, while the N2 domain forms a complex with the C-terminal domain of TolA at 
later stages. This interaction causes the release of the N1 domain from the intramolecu-
lar interaction with the N2 domain. Both of N1 and N2 domains are essential for the 
phage infectivity. Furthermore, the N-terminal part of p3 also prevents infected cell su-
perinfection by another filamentous phage. The CT domain is buried in the phage parti-
cle and takes part in the final stages of virion assembly on inner bacterial membrane 
(Russel et al., 2004; Bratkovič, 2009).  
 
Figure 3 Schematic representation of minor coat protein pIII structure (Adapted from Russel et al., 
2004). From N- to C-terminus, the domains of pIII are N1, N2, and CT which are linked with glycine-rich 
linker regions.  
 
If only the gene encoding for the foreign protein is inserted after the gene for 
pIII in the ssDNA of phage, it is called type 3 display. In the type 3 display, one copy of 
the gene of pIII is inserted, and five copies of foreign proteins are displayed.  In order to 
reduce the copy number of displayed foreign protein, two modifications are often made. 
One is type 33 display, both gene encoding for the wild-type pIII (without fusion) and 
gene encoding for the pIII fused with foreign protein are inserted in the ssDNA. There-
fore, there are both wild-type pIII and pIII with fusion protein exist on the new pro-




phagemid was introduced (Figure 4). Phagemid have the both features of plasmid and 
phage vector. It carries antibiotic resistance and enables replication of dsDNA, also it 
allows for production and packing of ssDNA into virions. Phagemids are engineered to 
express recombinant pIII fusions under controlled conditions. Helper phages, which 
belong to Ff phage, are essentially required in the type 3+3 display. They contain the 
gene encoding for all the remaining phage proteins which are essential in phage particle 
produce, and a compromised origin that leads to inefficient packaging. With infected by 
helper phage, the bacterial host having phagemid can express the wild-type phage pro-
teins from the helper phage genomes and a small amount of the fusion protein encoded 
by the phagemid (Bratkovič, 2009). 
 
 
Figure 4 Schematic view of a M13 filamentous bacteriophage from phagemid pAffi-100-Zlib-Tryp 
(Modified from Hedberg, 2003). The phage particle contains phagemid vector pAffi-100-Zlib-Tryp which 
is surrounded by several different coat proteins. Foreign protein - affibody- is displayed and fused on full-
length pIII.  
 
Potential binders may be selected for their binding properties from a large li-
brary. A typical phage display selection cycle is shown in Figure 5. The selection pro-
cess is achieved by incubating the phages particles to immobilized targets and then 
washing away unbound phages. The selection pressure is influenced by the antigen con-
centration, washing times and concentration of a competitor antigen added. Bound 
phages are eluted via low pH, high pH, or enzymatic cleavage. The eluted phages have 
the ability to infect E. coli cells and get enriched with helper phage. This process is also 
called phage panning.  After several rounds of enrichments, the potential binders could 
be selected (Bradbury and Marks, 2004; Grimm, 2007).  
Because of the presence of non-selectively binding phages, more than one selec-
tion cycles are required. The selection pressure increases in the consecutive selections. 
Furthermore, a pre-selection is performed in order to avoid undesired binding phages. 
The phage library is loaded to the solid support without the target, before exposed to the 
target molecule. The concentration of phage is evaluated by the titers, so it shows the 
effect of selection and enrichment of binding phages after phage production. In the post-
selection analysis, the selected clones are screened for the binding properties. After-
wards, the most promising candidates are prepared for further traits test (Bradbury and 
Marks, 2004; Grimm, 2007).  
Since phage is with high robustness and few costly laboratory reagents or 






Figure 5. Illustration of a typical phage display selection cycle (Derived from Grimm, 2007). Initially, 
library containing phage pool is exposed to immobilized antigen (target). Then, non-bound and weakly-
bound phages are removed in wash steps. Bound phages are eluted off and used to infect E-coli cell. The 
infected cells are stored for post-selection analysis or for phage produce before a new selection cycle  
2.2.2 Cell surface display 
In cell surface display, foreign peptides and proteins of interest are expressed on the 
surface of microbial cells. It is allowed to monitor the phenotype of the cell during se-
lection using quantitative flow cytometric analysis (Grimm, 2007). The protein to be 
displayed can be fused to a carrier protein by N-terminal fusion, C-terminal fusion or 
sandwich fusion (Lee et al., 2003; Grimm, 2007).  
Gram-negative bacteria surface display 
Gram-positive bacteria have a complex cell envelope structure consisting of the cyto-
plasmic membrane, periplasm and outer membrane. Therefore, the proteins need to 
cross two membranes and reach the extracellular milieu (Lee et al., 2003).  
The N-terminal fusion approach is used when there is a directing and anchoring 
domain in the C-terminus of the carrier protein. Peptidoglycan-associated lipoprotein 
(PAL) is regarded as a good example of the N-terminal fusion approach. The C-terminal 
portion of PAL binds to the peptidoglycan layer, while the N-terminal cysteine with 
lipid moiety modification binds to the outer membrane (Dhillon et al., 1999). The C-




quences on their N-termini. One typical carrier protein of this type is the Lpp-OmpA 
hybrid. The Lpp part is responsible for the proper localization to the outer membrane, 
while the OmpA part is related to the transportation of foreign proteins (Richins et al., 
1997; Lee et al., 2003). The most commonly used approach is the sandwich fusion for 
Gram-negative bacterial surface display. The carrier proteins used in this method can be 
divided into three classes: outer membrane proteins (OMPs), S-layer proteins, and sub-
unit proteins of extracellular appendages (Lee et al., 2003). OMPs form transmembrane 
β–barrels on the outer membrane. The short loops connecting antiparallel β-strains on 
the external side can potentially be used as fusion sites for foreign peptides and proteins. 
In one research, the peptide containing 162 amino acids was fused to E. coli OmpC (Xu 
and Lee, 1999). S-layer protein from Caulobacter crescentus possesses N-terminal do-
main binding to the outer membrane, and C-terminus having a secretion signal (Bingle 
et al., 1997). In E. coli, the subunit proteins of flagella and fimbriae can be applied to 
display foreign proteins. The subunit proteins attached by heterologous sequences are 
still possible to assemble into polymetric appendages (Westerlund-Wikström et al., 
1997; Stentejerg-Olesen et al., 1997) 
E. coli is one of the most commonly used Gram-positive bacteria host, it is an 





copies of library members displayed on a single E. coli cell. If the cell incubated with an 
antigen with fluorescent label, the fluorescence signals detected by flow cytometry are 
correlated with the affinity and the copy number of the displayed library members on a 
cell (Francisco et al., 1993). However, the fragility of outer membrane is still a problem 
due to the display of proteins (Lee et al., 2003).  
Gram-positive bacteria surface display 
Gram-positive bacteria have a single cell membrane and a thick layer of proteoglycan. 
Proteins displayed must be attached to the cell envelope when Gram-positive bacteria 
are used as host for the surface display. They can be linked either to the cytoplasmic 
membrane or cell wall components. Four major types of displayed proteins were dis-
cussed in the review by Desvaux and his colleague, they were a) proteins anchored to 
the cytoplasmic transmembrane, b) lipoproteins covalently attached to the membrane 
lipids after cleavage by signal peptidase II, c) proteins possessing C-terminal LPXTG-
like (in single-letter amino acid code, where X denotes any amino acid) motif and cova-
lently attached to peptidoglycan by sortase, and d) proteins recognizing some cell wall 
binding domains (Desvaux et al., 2006).  
Staphylococcal protein A (SPA) has been used as a model to analyze the anchor-
ing mechanisms of surface proteins, and it contains LPXTG-like motif followed by a 
hydrophobic domain and a charged tail. The LPXTG can be cleaved by sortase (SrtA) in 
the polypeptides between the threonine and the glycine. The hydrophobic domain serves 
as a membrane-spanning region, and the charged tail is regarded as a retention signal to 




1993). S-layer homology domain (SLHD) proteins possess cell wall binding domains. 
SLHDs are present as 1-3 SLD modules/motifs at the N-terminus of Gram-positive S-
layer proteins. S-layer proteins are able to bind very strongly to the cell wall via non-
covalent interactions (Mesnage et al., 1999). 
Staphylococcus carnosus is a food-grade bacterial strain, and it has been used 
for Gram-positive bacterial surface display. In 1995, Samuelson and co-workers con-
ducted a display of heterologous proteins on S. carnosus cells. It was also the first time 
to utilize fluorescence-activated cell sorting to analyze the presence of surface-displayed 
hybrid receptors on Gram-positive bacteria (Samuelson et al., 1995). Because of the 
significant increase in transformation efficiency, it was allowed for the display and 
screening of the first libraries (Löfblom et al., 2007). The first high-complexity protein 
library displayed on the surface of Gram-positive bacteria was constructed in the year of 
2007 (Nina et al., 2008).   
 Yeast surface display 
Yeast surface display was introduced by Boder and Wittrup research group in 1997. In 
the report, the selection of scFv antibody fragments against three-fold decreased antigen 
dissociation rate from a library displayed on Saccharomyces cerevisiae was performed. 
The library was fused to the C-terminus of the mating adhesion receptor (Boder and 
Wittrup, 1997). 
There are two types of mannoproteins present in the cell wall of S. cerevisiae: 
sodium dodecyl sulfate (SDS)-extractable and glucanase-extractable mannoproteins. 
The SDS-extractable mannoproteins are non-covalently bound to the cell wall, and they 
are able to be extracted by using SDS and reducing agents. The glucanase-extractable 
mannoproteins are linked to β-glucan of the cell wall via covalent bond, and it is possi-
ble to get them released by digestion with β-glucanase. Generally, the glucanase-
extractable mannoproteins have a putative glycosyl phosphatidylinositol (GPI) attach-
ment signal at the C-terminus (Van der Vaart et al., 1997; Lee et al., 2003). GPI anchor 
is required for the covalent association of these proteins with the cell wall due to the 
secretory pathway. The display of foreign peptide and protein is achieved by fusion to a 
mannoprotein. S. cerevisiae α-agglutinin, a-agglutinin, and flocculin has been used as an 
anchor protein (Kondo and Ueda, 2004). Almost all the yeast surface display applica-
tions are GPI anchor-dependent (Lee et al., 2003). 
There are unique advantages for yeast surface display. Yeast is a eukaryote, and 
it is recognized as safe in food and pharmaceutical applications. Also, it is able to dis-
play proteins with post-translational modification and having large molecular mass. It 
was found that yeast display could yield more high affinity clones compared to phage 
display, when using the same library towards the same antigen (Bowley et al., 2007). 
Furthermore, yeast display has become more and more popular since 1997. It was pos-
sible to improve the affinity of a scFv for fluorescein biotin to as low as 48 fM (Boder 




2.2.3 Ribosome display 
Ribosome display is a display system which does not rely on living cells to link geno-
type and phenotype. There are two main advantages for ribosome display: a) the diversi-
ty of the library is only limited by the number of ribosomes and different mRNA mole-
cules, b) it is easy to introduce random mutations after each selection round (Zahnd et 
al., 2007). The first description about ribosome display for peptides was reported by 
Mattheakis and co-workers in 1994 (Mattheakis et al., 1994). 
The concept of ribosome display is very simple to understand, and the core point 
is to translate an mRNA molecules library with stoichiometric quantity of ribosomes 
(Lipovsek and Plückthun, 2004). In principle, a library of DNA without stop codon is in 
vitro transcribed into the library of mRNA. Then, the mRNA library is in vitro translat-
ed. The translation of mRNA performed in cell extracts of E. coli, wheat germ or rabbit 
reticulocytes. E. coli S-30 extracts are the most frequently used for translation in ribo-
some display, because of containing ribosome-associated factors which are important 
for protein folding. Because of the lack of stop codon in mRNA, the ribosome will fre-
quently get the very end of mRNA molecules. Also, the end of the newly synthesized 
polypeptide is still within the ribosomal tunnel, and its last amino acid is still connected 
to the peptidyl-tRNA. Therefore, a ternary complex is formed with mRNA, ribosome 
and the corresponding polypeptide, and the mRNA connects between the phenotype 
(the protein) and genotype (the mRNA). The complexes serve as library members and 
enter a selection cycle, where the principle is similar to the one in the phage display. 
After each cycle of selection, the complexes with binding targets isolated, and reverse 
transcribed into DNA which is followed by the PCR amplification.  The new template is 
generated and prepared for the next selection cycle (Figure 6) (Lipovesk and Plückthun, 
2004; Grimm, 2007; Hoffmann et al., 2010). 
 
Figure 6. Illustration of a typical ribosome display selection cycle (Derived from Grimm, 2007). DNA 
encoding the library without stop codon is in vitro transcribed into mRNA. The mRNA library lack of 
stop codon is in vitro translated, and the complexes of mRNA-ribosome-protein are formed. Then, the 
stabilized complexes are exposed to the immobilized antigen. Non-binding complexes are washed away, 
and the binding ones are eluted and purified. Isolated mRNA is either reverse transcribed and amplified, 




A typical structure of linear DNA template in prokaryotic ribosome display sys-
tem is shown in Figure 7. T7 promoter is essential in the DNA template for the tran-
scription, and it allows for mRNA synthesis. The followed ribosome binding site (RBS) 
is able to base-pair with ribosomal RNA, which is Shine-Dalgarno (SD) sequence. SD 
sequence is related to the initiation of translation. The gene for polypeptide to be dis-
played is inserted after RBS. A spacer protein is also needed for the fold flexibility of 
proteins. Generally, at least 23-30 amino acids are required as spacer protein (He et al., 
2005; Grimm, 2007).  
 
Figure 7. A typical linear DNA template in prokaryotic ribosome display (Derived from Lipovsek and 
Plückthun, 2004). T7 is the T7 promoter for the start of mRNA synthesis. SD serves as RBD. Spacer is 
attached after the polypeptide to display. 5’sl and 3’sl denotes the stem loops on the 5’- and 3’-ends of the 
mRNA respectively. 
 
The first complex library tested for selection and affinity maturation by ribo-
some display was the one of antibody scFv fragments. The library was generated from 
immunized mice. It was able to functionally express scFv with good yields in the E. coli 
extracts, and the lowest dissociation constant of scFv could reach (4±1)×10
-11
 M (Hanes 
et al., 1998). Afterwards, synthetic library was introduced into the ribosome display 
system. In the study, scFv from a large synthetic library was selected and evolved again 
bovine insulin, and their equilibrium dissociation constants are as low as 8×10
-11 
M. 
Also, error-prone PCR was used for point mutations in this study, and it allowed a 40-
fold increase in affinity when compared to the progenitor clones (Hanes et al., 2000).  
2.3 Affibody molecule 
2.3.1 Affibody technology 
Affibody molecules consist of 58 amino acids and whose relative molecular mass is 
about 6.5 kDa. There are three α-helices in the structure (Figure 8). Affibody molecules 
were originally derived from the B-domain of SPA. In the G29 of B-domain, Gly was 
substituted by Ala. This engineered variant was called Z domain. The G29A mutation 
enabled Z domain to enhance chemical stability, and increase the folding rate constant 
by threefold as well. The engineered Z-domain still had the affinity for the Fc part of the 
antibody but almost lost the weaker affinity for the Fab region (Arora et al., 2004; 
Löfblom et al., 2010). Affibody molecules were initially described in 1996. These small 
binding proteins were achieved by randomization of 13 solvent-accessible surface resi-




one of the highest affinity of an Affibody molecule is 22 pM for the breast cancer mark-
er Her2 (Nord et al., 2006). 
Affibody molecules are a new class of affinity ligands, which have the similar 
functions to those of antibodies. They are regarded as a viable and sometimes superior 
alternative to antibodies. When compared with antibody, Affibody molecule is non-
immunoglobulin-based, and the isolation is performed using synthetic combinatorial 
libraries and in vitro selection systems. Also, the frameworks for building Affibody 
molecules are smaller and structurally less complex than immunoglobulins, which 
brings the advantages to both production and application issues. Affibody molecules 
have the proven potential for therapeutic, diagnostic and biotechnological application 
(Löfblom et al., 2010).  
 
 
Figure 8. Schematic view of the Z domain of Affibody scaffold (Derived from Grönwall, 2008). Z do-
main is derived from the B domain of SPA which contains five IgG-binding domains. 13 surface-located 
amino acid residues in helices 1 and 2 have been used to create combinatorial protein libraries. 
 
First-generation Affibody libraries have been constructed through the genetic 
randomization of 13 amino acids which are located on the surface of the Z-domain scaf-
fold. The randomization positions are determined by the analysis of an available X-ray 
crystallography structure of the co-complex between the homologous B-domain of SPA 
and human IgG (Deisenhofer, 1981). These 13 positions are all in helices 1 (7 positions) 
and helices 2 (6 positions) of the three-helix bundle. Most of the 13 positions are related 
to the interaction with Fc region of human IgG1. With 32 codons and 20 amino acids, 













egies applied to increase the affinity of members selected from the first-generation li-
brary. One is to keep the highly conserved binding residues constant and randomize the 
remaining binding positions after post-selection analysis, and make a re-selection 
against the same target. The other one is construct multivalent Affibodies from a select-
ed monomeric Affibody (Steffen et al., 2005; Orlova et al., 2006; Sawyer et al., 2013). 
Second-generation Affibodies are designed by scaffold optimization. Site-specific mu-
tagenesis of residues outside the binding surface was used to improve properties of Af-
fibody molecule (Feldwisch et al., 2010).  
Affibody can be obtained and enriched by in vitro selection. For example, phage 
display has been used to identify library members. A large scale of a specific Affibody 
is able to be produced chemical synthesis or prokaryotic expression (Rönnmark et al., 
2002; Engfeldt et al., 2005).  
2.3.2 Applications 
2.3.2.1 Biotechnology 
Affibody molecules have been used for targeting various proteins, and regarded as the 
capturing agents on affinity chromatography columns for protein purification. In one 
research, Affibodies were selectively bound to bacterial Taq DNA polymerase and hu-
man apolipoprotein A-1M, respectively. It was possible to efficiently recover both target 
proteins from crude cell lysates when using these two Affibodies in affinity chromatog-
raphy. Both column capacity and selectivity kept the same in repeated cycles of sample 
loading, washing and low pH elution (Nord et al., 2000). Furthermore, Affibody has 
successfully applied for selective binding to human IgA. First, phage display technology 
was used to selective Affibodies binding to IgA monoclonal antibodies. It was shown 
that five out of eight selective Affibodies were capable of IgA after biosensor technolo-
gy applied. The lowest dissociation constants (Kd) reached 0.5µM. ZIgA1 with strongest 
binding affinity also showed the ability to selectivity recognize human IgA subclasses 
(IgA1 and IgA2) and secretory IgA. In further analysis, ZIgA1 was constructed as divalent 
head-tail dimer in affinity column, and able to recover IgA protein from a spiked E. coli 
cell lysate in affinity chromatography (Rönnmark et al., 2002). Another application 
showed Alzheimer amyloid β (Aβ) peptides binding Affibody. It was reported that se-
lected Affibody molecules could efficiently capture Aβ peptides from human plasma 
and serum (Grönwall et al., 2006).  
Due to the small size and favorable biophysical properties of Affibody mole-
cules, they have widely applied in other biotechnology areas traditionally dominated by 
antibodies. Various proteins have been linked to Affibody molecules which enabled 
facile detection of targets in assays. Affibody specific to surface protein G of respiratory 
syncytial virus (RSV) was genetically fused to the Fc fragment of human IgG, and led 
to Affibody-Fc chimeras. The chimeras were demonstrated to efficiently detect targets 




ment (Rönnmark et al., 2002). Affibody was also reported to link various enzymes. The 
enzyme β-galactosidase (β-gal) was conjugated with Affibody ZIgA1, which resulted in 
two kinds of chimeras: ZIgA1-β-gal and (ZIgA1)2-β-gal. They were applied to detect IgA 
in enzyme-linked immunosorbent assay (ELISA) and dot-blot analyses (Rönnmark et 
al., 2003). Fusing Affibody, targeting IgA and IgE, to the bacterial surface protein made 
it possible to use whole-cell analysis in agglutination assays or whole-cell immunepre-
cipitations (Gunneriusson et al., 1999).  
Affibody also serves as affinity probes in protein micro-array formats. In one 
study, dimeric Affiobdy molecules targeting IgA, IgE, IgG, TNFα, Insulin and Taq pol-
ymerase, respectively, were immobilized on thiol dextran microarray slides. After the 
slides incubated with fluorescently labeled, specific binding of respective target proteins 
was observed without cross-reactivity. The detection limit of the best performing Af-
fibody was about 70fM (Renberg et al., 2007). In the same research, Affibody mole-
cules were also used as capture agents in a sandwich array format where unlabeled pro-
tein and monoclonal antibodies were specifically selected in serum or plasma sample 
(Renberg et al., 2007).   
Fluorescent molecules are able to couple to Affibody molecules. Oregon Green 
488 dye was conjugated to a C-terminal cysteine of a HER2 targeting. Then, flow cy-
tometry and immunefluorescent confocal microscopy were used to analyze HER2 ex-
pression levels on cancer cell lines and cryosections of SKOV-3 xenograft tumors 
(Lundberg et al., 2007). Another similar research was focused on the HER2 and EGFR-
specific Afffibody which fused to fluorescent proteins. The expression levels of HER2 
and EGFR on cell lines and in tissue were measured via flow cytometry and confocal 
imaging (Lyakhov et al., 2010).  
Furthermore, Affibody molecules have been investigated as biosensor to detect 
analytes by fluorescence resonance energy transfer (FRET). Affibody molecules with 
the specific affinity for IgA and IgG, respectively, were labeled with EDANS and 
NBDX which were site-introduced at opposite ends of Affibody molecules. The do-
nor/acceptor pair enabled FRET. As well, a biotin moiety was labeled on the Affibody 
for surface immobilization. Fluorescent-labelled protein was titrated with increasing 
concentration of protein, and it showed shifting relative emission of the fluorescent 
probes (Engfeldt et al., 2005).  Another research based on FRET for specific detection 
of target proteins used antiidiotypic Affibody pairs. Idiotypic target-specific Affibody 
was labeled with fluorescein, while antiidiotypic Affibody was labeled with tetra-
methylrhodamine. These two Affibodies were used in a homogeneous competitive bind-
ing assay, where intramolecular FRET between the two fluorescent probes was gained 
in the antiidiotypic Affibody complex. However, the FRET signal decreased with the 








Imaging is an important area where Affibody is applied to detect the lesions in the body. 
The radiolabeled Affibody has shown great advantages in single-photon emission spec-
troscopy (SPECT) and positron emission tomography (PET). The half live of Affibody 
is shorter than positron emitting nuclides and gamma emitting nuclides (Orlova et al., 
2006).  
The cancer-specific cell-surface receptor HER2 was traced with HER2-binding 
Affibody for imaging. HER2 is a transmembrane protein, and belongs to the human 
epidermal growth factor tyrosine kinase receptor family. It was reported to overexpress 
in several cancer types, such as 23% to 30% in breast and ovarian cancers (Wang et al., 
2001). The detection of HER2 expression is suggested in the tumor lesions diagnosis. 
HER2-binding Affibody was selected out from the naïve phage library, and showed the 
great ability to bind to HER2 protein in SKOV- 3 which is a human ovarian carcinoma 
cell line. Moreover, studies in rats were performed. Affibody was observed to get en-
riched within one hour after the tail vein injection. Due to the rapid blood clearance, it 
was allowed to image tumors in mouse xenografts models in 30-60 minutes after injec-
tion.  Furthermore, it was possible to label Affibody with 
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Tc (t2/1 6h), and 
111
In (t2/1 2.8 days) to extend the half live of Affibody. How-
ever, antibodies and scFv or Fab fragments are not well compatible with short-lived 




Ga.  Also, Affibody has smaller size and faster bio-
distribution compared with antibodies and scFv or Fab fragments (Löfblom et al., 
2010).  
 Site-specific labeling of Affibody allows the clinical utilization. Labeling can 
be achieved by site-specific coupling of a chelator during peptide synthesis, or by in-
corporation of a unique cysteine and using thiol-directed chemistry (Löfblom et al., 
2010). The first site-specific radiolabeling Affibody molecule was ZHER2:342, and it was 
produced via peptide synthesis. DOTA was attached to the N-terminal in the last syn-
thesis step to yield DOTA- ZHER2:342-pep2 (ABY002). Then, 
111
In was labeled to 
ABY002. The formed 
111
In-ABY002 was injected to the mice with SKOV-3 tumor. 
111
In-ABY002 was efficiently distributed in the body and bound to the HER2 overex-
pressing tumor. It always showed higher uptake in tumor than in other organs expect 
kidney. High tumor to blood ratio enabled the imaging of tumors in 1h after injection 
(Orlova et al., 2007). Another research using 
68
Ga as radiolabel on ABY002 showed 
analogic results (Tolmachev et al., 2010).  
Affibody can be dual-labeled to make a site-by-site comparison of two different 





gave the result that the tumor uptakes for both molecules were quite similar. However, 
there was significant higher radioactivity of 
111
In-ABY002 in blood, lung, spleen and 





applied to three patients with metastatic breast cancer. It took only 2-3h to obtain high 




11 amino acids in the scaffold of ZHER2:342 were engineered to obtain new HER2-
binding Affibody molecule ZHER2:2891 which have higher hydrophilicity and higher 
thermal stability. Maleimido-DOTA was attached to the C-terminal cysteine, yielding 
[MMA-DOTA-Cys61]-ZHER2:2891 - Cys (ABY025).  It was reported that 
111
In-ABY-025 
bound specifically to HER2 both in vitro and in vivo (Ahlgren et al., 2010). Another 
new molecule ZHER2:342-ABD035-DOTA (ABY027) was constructed by adding ABD035, 
which had a high affinity for human serum albumin, to the N-terminal of ZHER2:342 fol-
lowed by the conjugation of DOTA to the N-terminal of ABD035. 
177
Lu was used as ra-
diolabel for ABY027. At 48h after injection, tumor uptake of 
177
Lu-ABY027 was as 3-
fold as that for previously reported ABD-(ZHER2:342)2. ABY027 was suggested more 
suitable for therapy (Tolmachev et al., 2007; Jonsson et al., 2008; Orlova et al., 2013).  
Moreover, Affibody is applied in magnetic resonance imaging (MRI) which is a 
powerful tool for in vivo anatomical and molecular imaging. Superparamagnetic iron 
oxide (SPIO) particles targeted with HER2 Affibody enabled the image of HER2 in 
murine tumor xenograft (Kinoshita et al., 2010).  
2.3.2.3 Therapeutic applications 
One outstanding application of Affibody molecule is in therapeutic area. One hybrid 
protein, containing Affibody molecule as affinity recognition moiety and a toxic domain 
with therapeutic efficacy, is an outstanding payload. A novel recombinant Affitoxin was 
developed with the structure consisting of HER2-specific cytotoxic molecules and 
HER2-specific Affibody. The cytotoxic molecules were truncated from Pseudomonas 
exotoxin A (PE), which was a cell killing agent. In the report, Affitoxin could bind spe-
cifically to HER2 with nanomolar affinity, and it was demonstrated to treat HER2-
positive tumors (Zielinski et al., 2009).  
The success of Affibody utilization in imaging supports essential knowledge for 
therapeutic applications. Distribution of radionuclides labeled Affibody molecules ob-
tained from imaging enables the estimation of delivered dose and toxic effects. The cal-
culated dose of ZHER2:342 was tested by biodistribution studies with 
111
In label. The result 
from the study suggested that 
111
In-benzyl-DTPA-ZHER2:342 was a promising candidate 
for detection of HER2 expression in malignant tumors (Tolmachev et al., 2006). Anoth-
er 
186
Re-labeled HER2 specific Affibody conjugate maGSG- ZHER2:342 was demonstrated 
promising for therapeutic application (Orlova et al., 2010). The internalization of Af-
fibody molecule into malignant cells has also been concerned.  
111
In labeled DOTA- 
ZHER2:342-pep2 was studied on three HER2-expressing cell lines: SKOV-3, SKBR-3, and 
BT474. It was found that both continuous and interrupted incubation of tumor cells with 
111
In-DOTA- ZHER2:342-pep2 made a slow internalization, while the tracer strongly binding 
to the cell-surface receptors enabled a high level of cellular retention (Wallberg and 
Orlova, 2008).  
An albumin binding domain (ABD) was fused to a radiolabeled anti-HER2 Af-




fold increase in tumor uptake when compared with non ABD-fused Affibody. It was 
shown that 
177
Lu labeled Affibody-ABD chimera displayed specific binding to HER2-
expressing cells in vitro, and completely prevented formation of tumors when injected 
into mice with HER-2 expressing SKOV-3 ovary cancer microxenografts (Tolmachev 
et al., 2007).   
Liposomes can protect the elimination and degradation of encapsulated drugs, 
and they have been utilized with Affibody molecules. The cysteine-modified Affibody 
molecule targeting EGFR was chemically coupled to maleimide-PEG2000-DSPE. Subse-
quently the conjugate was inserted into PEGylated liposomes, which led to stabilized 
Affibody liposomes (SALs). These SALs could strongly and selectively bind to EGFR-
expressing tumor cell lines, also enable efficient internalization of the liposomes. The 
cytotoxicity to EGFR-expressing cells was imporved by using mitoxantrone-loaded 
liposomes (Beuttler et al., 2009). In another study, Afffibody ZHER2:342-Cys was conju-
gated with thermosensitive liposomes, and formed HER
+
 Affisomes which retained the 
thermosensitivity (Puri et al., 2008). In the following research, a spacer at the C-
terminus of the Affibody molecule was inserted, in order to enhance the binding ability 
to cell surface-expressed HER2 (Smith et al., 2011).  
Affibody has also been investigated with human adenoviruses (Ad) which used 
as vector in cancer gene therapy. Human adenoviruses are engineered to remove the 
binding ability to native receptors. Adenovirus type 5 (Ad5) was re-targeted to 
HER2/neu by the insertion of a dimeric Affibody molecule ZH in the HI-loop (Magnus-
son et al., 2007). Another Affibody molecule ZT targeting Taq polymerase was also 
inserted in the same HI-loop but at a different position. The engineered fiber with ZT-
ZH could bind to both targets, while the one with ZH-ZT could not (Myhre et al., 
2009).  
Various Affibody molecules have been demonstrated to block relevant protein 
interaction. For example, an ABD-fused Affibody specific for CD28 could inhibit reac-
tion between CD28- CD80. CD28 plays an important role in co-stimulatory signaling in 
T-cells (Sandström et al., 2003). The Affibody molecules specific for CD25 were se-
lected out from an Affibody phage library. The selected Affibody molecules were com-
petitive for the same binding site with IL-2 known as the natural ligand of CD25. The 
overexpression of CD25 was found in organ rejections, some antoimmune diseases, and 
T-cell malignancies. Therefore, CD-binding Affibody could be potentially used as tar-
geting agents (Grönwall et al., 2008). Epidermal growth factor HER3 is considered as 
key biomarker in cancer. Two promising HER3-specific Affibody molecules were 
demonstrated to bind targets on three HER3 overexpressing cancer cell lines. Mean-
while, heregulin (HRG), regarded as natural ligand of HER3, was blocked by addition 
of Affibody molecules. In vitro experiment, these two Affibody molecules completely 
inhibited the HRG-induced cancer cell growth (Göstring et al., 2012).   
Furthermore, Affibody molecules own the ability to block soluble protein lig-
ands. Affibody molecules targeting human TNF-α were selected an Affibody phage 




sue destruction. Twelve sequences of Affibody molecules were gained after selection 
and sequencing. After protein characterization, three kinds of Affibody molecules were 
demonstrated with strongest binding. The Affibody binding site was overlapped with 
the one for TNF-α receptor. Therefore, the interaction between TNF-α and its receptor 
could be efficiently blocked (Jonsson et al., 2010). Another research was focused on the 
amyloid-β (Aβ) peptides specific Affibody molecule in Alzheimer’s disease. Two se-
lected most promising Affibody variants were demonstrated to efficiently capture Aβ 
peptides spiked to plasma and serum samples. These Affibody molecules could be po-
tentially used for therapeutic application (Grönwall et al., 2006). Recently, a new Af-
fibody molecule, ZAβ3(12–58) specific for Aβ with sub-nanomolar affinity, was modi-
fied to lock the peptide in monomeric. It was indicated that engineered Affibody mole-
cules are useful for study metal-binding and other properties of monomeric Aβ (Lind-
gren et al., 2013).  
2.4 Ephrin-B3 
The largest known subfamily of receptor tyrosine kinases (RTKs) is Eph family (Bram-
billa and Klein, 1995). The corresponding ligands are called Ephrin. Ephrin are divided 
into two families based on the structure and function: One is Ephrin-A which is tethered 
to the cell surface by a glycosylphosphatidylinositol (GPI) linkage, while the other one 
is Ephrin-B which is transmembrane ligand (Flanagan and Vanderhaeghen, 1998). Gen-
erally, the Ephrin-A ligands activate the EphA receptors, while Ephrin-B ligands inter-
act with the EphB receptors. However, Ephrin-A5 is reported to bind and activate 
EphB2 receptors (Himanen et al., 2004), and another exception is that EphA4 can bind 
to both ephrin-A and ephrin-B (Kullander and Klein, 2002). In vitro, each Eph receptor 
binds multiple Ephrin ligands, and each ligand binds to multiple receptors (Pasquale, 
1997). The contact-dependent interactions between Eph and their Ephrin lead to Eph 
autophosphorylation on tyrosine and activation of RTK activity. The interactions are 
involved in mediating and regulating cell migration and axon pathfinding (Flanagan and 
Vanderhaeghen, 1998). 
Ephrin-B3 is an approximately 50kDa protein encoded by the EFNB3 gene, and 
it belongs to the Ephrin-B class. Ephrin-B3 is highly expressed in brain, and important 
in brain development and in its maintenance. It has been demonstrated to play key roles 
to regulate axon guidance at the ventral midline of the embryonic mouse spinal cord 
(Kadison et al., 2006). Furthermore, Ephrin-B3 is likely involved in tumorigenesis (Fox 
and Kandpal, 2004). It was illustrated that ephrin-B3 expression and phosphorylation 
were associated with increasing tumor grade in in human glioma cells (Nakada et al., 
2006). Ephrin-B3 was described as a putative signaling molecule in the combined 
treatment of non-small cell lung carcinoma cells with PKC 412 and ionizing radiation. 
Increased cell death response was observed after inhibition of Ephrin-B3 expression 




3. MATERIALS AND METHODS 
General: All PCR extensions were performed by GeneAmp® PCR System 9700 (Ap-
plied Biosystems) using Phusion DNA polymerase (Finnzymes) and oligonucleotide 
primers (Eurofins MWG Operon). PCR products were purified with QIAquick PC  puri-
fication Kit (Qiagen). DNA restriction enzymes were the product from New England 
Biolabs. Different centrifuges Heraeus Multifuge 3SR (Thermo), and Avanti J-26XP 
(Beckman Coulter) were applied. DNA sequencing was performed by 3730XL DNA 
Analyzer (Life Technologies). 
3.1 Phagemid Vector Engineering  
3.1.1 Phagemid vectors 
The phagemid vector pAffi-100-Tryp (Figure 9) was constructed from pAffi1 (Grön-
wall et al., 2007). There was a full-length g3p (D1, D2, and D3) in pAffi-100-Tryp, 
while there was a truncated g3p (D3) in pAffi1. Also, there was a new element Trypsin 
site before the full-length g3p in pAffi-100-Tryp. The phagemid vector pAffi-100-Tryp 
was constructed in three steps. 
 
 
Figure 9. The phagemid vector pAffi-100-Tryp. Dummy fragment was kept in the position where Zlib 
should be inserted. There was an amber stop and a Trypsin site between ABD and g3p. This phagemid 





In the first step, the gene fragments Helix3 and ABD following by introducing a 
trypsin cleavage site was obtained by using oligonucleotide primers DOLI1 (5’-
GAAGCTT GCTAGCAGAAGCTAAAAG-3’; underline: NheI recognition site) and 
DOLI2 (5’-AGCCCCAGCACGGCGGGCCCCCTACCCGGGTACGTAAGGTAA-3’; 
underline: sequence complementary to DOLI3), and pAffi-1 was as template. The PCR 
reaction was performed with program consisting of initial denaturation at 98℃ for 30s, 
30 cycles of denaturation 98℃/10s, annealing 61℃/30s and extension 72℃/15s, and 
final extension at 72℃ for 10 minutes. The sample was kept at 4℃ after completion. 
The other PCR reaction to get gene fragment full length g3p was carried out with the 
template pM13cp (Chastten et al., 2006), as well as the primers DOLI3 (5’-
GGGGCCCGCCGTGCTGGGGCTGAAACTGTTGA AAGTTGTTTTA-3’; underline: 
sequence complementary to DOLI2 for overlapping PCR) which also contained a tryp-
sin site, and DOLI4 (5’-GAAAATTCATATGGTTTACAGCGC-3’; underline: NdeI 
recognition site). The PCR program consisted of initial denaturation at 98℃ for 30s, 30 
cycles of denaturation 98℃/10s, annealing 59℃/30s, and extension 72℃/30s, and final 
extension at 72℃ for 10 minutes, and holding at 4℃ after completion.   
Second, an overlap PCR was performed with the amplified PCR fragments He-
lix3 and ABD from pAffi1 and g3p from pM13cp, because there was a complementary 
part between DOLI2 and DOLI3. The outer primers DOLI1 and DOLI4 were added. 
The overlap-PCR program contained initial denaturation at 98℃ for 30s, 30 cycles of 
denaturation 98℃/10s, annealing 61℃/30s and extension 72℃/30s, and final extension 
at 72℃ for 10 minutes, and holding at 4℃ after completion. The PCR product was an 
overlapped fragment consisted of Helix3and ABD, Trypsin site, and g3p. This PCR 
fragment was purified via gel extraction.  15µl PCR product was mixed with 3µl 6X 
Loading Dye, and loaded in the well of 0.75% agarose gel stained with Ethidium Bro-
mide. The electrophoresis was set for 25 minutes with 120V.  The band of overlapped 
fragment was cut and purified with QIAquick Gel Extraction Kit (Qiagen).  
In the third step, the overlapped fragment was inserted between the NheI and 
NdeI sites of pAffi1.  Approximately 180ng of overlapped fragment was digested in 
40µl volume reaction which included 10 units NheI-HF®, 10 units NdeI, 1X BSA, and 
1X NEBuffer 4. The mixture was incubated at 37˚C for 1 hour, and deactivated at 80˚C 
for 20 minutes. There was approximately 6µg pAffi1 vector digested in 50µl volume 
reaction with 40 units NheI-HF®, 40 units NdeI, 1X BSA, and 1X NEBuffer 4. The 
digestion was performed at 37˚C for 2 hours, and the inactivation was processed at 80 
˚C for 20 minutes. Both of the digestion products were verified by electrophoresis on 
1% agarose gel stained with Ethidium Bromide. 2µl of the PCR product was mixed with 
2µl 2X Loading Dye, and loaded in the well. The electrophoresis was set for 25 minutes 
with 150V.  The digested pAffi1 vector was purified by gel extraction. 50µl of digested 
pAffi1 vector was mixed with 10µl 6X Loading Dye. The mixture was loaded in the 
0.75% agarose gel stained with Ethidium Bromide. The electrophoresis was set for 25 




Aquick Gel Extraction Kit (Qiagen).  The digested overlapped fragment was purified by 
QIAquick PCR Purification Kit (Qiagen).  
Both of the purified digestion products were ligated in a 30µl volume reaction 
including approximately 50ng digested pAffi1 vector, approximately 80ng digested 
overlapped fragment, 1X T4 DNA Ligase Buffer(New England Biolabs), and  300 units 
T4 DNA Ligase (New England Biolabs). The mixture was incubated at RT for 1 hour. 
The ligation product was named as pAffi-100-Tryp.  
3.1.2 DNA sequence analysis 
In order to verify the sequence correction of phagemid pAffi-100-Tryp, it was trans-
formed in to E.coli strain Top 10 via heat shock. 2µl of ligation product was mixed with 
8µl of 5X KCM buffer (500mM KCl, 150mM CaCl2, and 250mM MgCl2). After 3 
minutes incubation on ice, the mixture was added into 10µl of thawed Top 10 competent 
cells. Then, it was left on ice for 20 minutes, and moved back to RT for 10 minutes. The 
mixture was taken back on ice for another 3 minutes. Following adding 200µl of 
TSB+Y medium, the mixture was rotated e-o-e for 1 hour at 37 ℃, and spread on agar 
plate with Amp 100µl/ml. The plates were placed in 37℃ overnight.  
8 colonies were picked for sequencing. These colonies were diluted with Milli-
Q, and served as template for PA-PCR reaction. Primers DOLI4 and E’ (5’-
GCGCAACACFATGAAG-3’) were used. The PA-PCR reaction was performed in 
25µl reaction volume including 0.2µl Taq DNA polymerase, 1X Taq buffer, 0.1µM 
forward primer E’, 0.1µM reverse primer DOLI4, and 100µM dNTP. The program con-
tained initial denaturation at 94℃ for 5 minutes, 35 cycles of denaturation 94℃/40s, 
annealing 59℃/40s and extension 72℃/1min40s, and final extension at 72℃ for 8 
minutes, and holding at 4℃ after completion. The PCR product verified by electropho-
resis on a 1% agarose gel stained with Ethidium Bromide. 2µl of the PCR product was 
mixed with 2µl 2X Loading Dye, and loaded in the well. The electrophoresis was set for 
25 minutes with 150V. The PCR fragments with correct length were saved for Cy-seq 
PCR. Cy-seq PCR was performed in 10µl reaction volume including 2 µl PA-PCR 
product as template, 0.5µl Big Dye, 1X CS buffer, and 0.5µM primer X (X stood for 
one of the five primers DOLI1, DOLI2, DOLI3, DOLI4, and E’ which were used for 
Cy-seq PCR reaction separately). The program was set with initial denaturation at 95℃ 
for 30s, 35 cycles of denaturation 96℃/10s, annealing 50℃/5s and extension 60℃/4min, 
and final extension at 60℃ for 4 minutes, and holding at 4℃ after completion.  
Ethanol precipitatation 
After Cy-seq PCR, the PCR products were handled with ethanol (EtOH) precipitate in a 
96 well plate. In the first step, 25µl 95% EtOH and 1µ 3M CH3COONa (pH=5.2) were 
mixed well with 10µl Cy-PCR product, and the mixtures was spun at 3200g and 4˚C for 




75µl 75% EtOH was added, and the plate was centrifuged at 3200g and 4˚C for 30 
minutes. After all supernatant removed, the plate was kept in dark place for drying out. 
At last, 20µl Milli-Q was added, and the plate was sent for sequencing.  
The colonies with correct sequence were picked out, and inoculated in 10ml 
TSB+Y medium with 100µg/ml Amp and cultivated at 37℃ overnight. The cells were 
harvested for plasmid extraction by QIAprep ® Spin Miniprep Kit (Qiagen). 
3.2 Comparative Test Selections with Low pH acid and Trypsin 
elution 
3.2.1 Preparation of phagemid pAffi-100-Tryp-Zwt and pAffi-100-
Tryp-ZHer2:342 
In order to test the new system, a comparative test was applied. The test selections were 
performed with the phage particle mixtures only containing ZWT and ZHer2:342. The 
phagemid pAffi-100-Tryp-ZWT and pAffi-100-Tryp-ZHer2:342 were prepared from 
phagemid pAffi-100-Tryp where the dummy fragment was replaced by gene fragment 
coding Helix1 and Helix2 which served as the randomization part of the library. Both of 
the DNA fragment (ZWT) coding Helix1 and Helix2 of ZWT and DNA fragment 
(ZHer2:342) was amplified separately.  
The PCR product of ZHer2:342 was purified by gel extraction. 35µl PCR product 
was mixed with 7 µl 6X Loading Dye, and loaded in the well of 0.75% agarose gel 
stained with Ethidium Bromide. The electrophoresis was set for 25 minutes with 130V.  
The band of ZHer2:342 was cut and purified with QIAquick Gel Extraction Kit (Qiagen). 
The PCR product of ZWT was purified by QIAquick PCR purification kit (Qiagen).  
Both of the phagemid pAffi-100-Tryp and insert DNA fragment coding Helix1 
and Helix2 of ZWT and ZHer2:342 were digested with restriction enzyme XhoI and NheI-
HF®.  
Approximately 7.8ng phagemid pAffi-100-Tryp vector was digested in 40µl 
volume digestion reaction with 20 units NheI-HF®, 20 units XhoI, 1X BSA, and 1X 
NEBuffer 4. The digestion was performed at 37˚C for 1 hour, and the inactivation was 
processed at 60˚C for 20 minutes. The digested pAffi-100-Tryp vector was purified by 
gel extraction. 30µl of digested phagemid pAffi-100-Tryp vector was mixed with 7µl 
6X Loading Dye. The mixture was loaded in the 0.75% agarose gel stained with Ethidi-
um Bromide. The electrophoresis was set for 25 minutes with 130 V.  The band of di-
gested pAffi-100-Tryp vector was collected and purified with QIAquick Gel Extraction 
Kit (Qiagen).  
Ligation reactions were performed for each insert pAffi-100-ZWT-Tryp and pAf-
fi-100-ZHer2:342-Tryp. The ligation for insert ZWT was prepared in 20µl volume reaction 
contains approximately 38ng digested DNA fragment ZWT, approximately 52ng digest-




while the ligation for insert ZHer2:342-Tryp was also made in 20µl volume reaction which 
includes approximately 45ng digested DNA fragment ZHer2:342-Tryp, approximately 
52ng digested pAffi-100-Tryp vector, 1X T4 DNA ligase buffer, and 200 units T4 DNA 
ligase. All of the ligations were incubated at RT for 1 hour. The ligation products were 
called pAffi-100-ZWT-Tryp and pAffi-100-ZHer2:342-Tryp. The ligation products were 
used for heat shock transformation with E. coli strain Top 10 cell. After transformation, 
the cells were spread on agar plate with 100µg/ml Amp and left at 37℃ overnight. 24 
colonies were picked up from overnight culture of ZWT and ZHer2:342 for sequencing. PA-
PCR and Cy-seq PCR were performed as mentioned in Section 2.1.2. The colonies with 
correct sequence were saved for phage particle preparation.  
3.2.2 Helper phage preparation  
ER2738 cell (Lucigen) was cultivated in 50ml TSB medium with 10µg/ml Tet. The 
flask was shaken at 37℃ with 120 rpm. When the value of O.D. 600 reached 0.5-0.8, 
10µl of helper phage KM13 (1.0×10
11
 pfu/ml, Creative Biolabs) was added. The flask 
was incubated at 37˚C without shaking, which was followed by half hour slowly shak-
ing. Then, the mixture was transfer to 500ml TSB+Y medium with 50µg/ml Kanamycin 
and 10µg/ml Tet, which was shaken at 30℃ with 100 rpm about 16-18 hours.  
PEG 6000/NaCl precipitation 
The overnight cultured helper phage KM13 was centrifuged at 3000g for 20 minutes at 
4℃. The supernatant was transfer to a new tube for PEG/NaCl (20% (w/v) PEG6000, 
and 2.5M NaCl) precipitation. After 1/4Vol PEG/NaCl added, the mixture was incubat-
ed on ice for 1 h. Then, it was centrifuged at 10500 g for 40 minutes at 4℃. The super-
natant was poured off, and the phage pellet was resuspended in 1/20Vol 1X PBS buffer 
(154mM NaCl, 8.1mM Na2HPO4, and 1.9mM NaH2PO4*H2O). The sample was re-
moved into SS-34 tubes, and 1/4Vol PEG/NaCl was added. After 45 minutes incubation 
on ice, the sample was centrifuged at 12000g for 40 minutes at 4℃. The supernatant 
was poured off, and the pellet was resuspended in 2ml 1X PBS buffer.  With another 
centrifuge at 13000g for 1min and filtration with 1.2µm and 0.45µm filter, the KM13 
helper phage was collected. It was separately titrated with E. coli strain ER2738 on agar 
plates with Amp, plates with Km, and plates with Tet. The rest helper phage was stored 
at -20˚C after adding 1Vol 80% Glycerol.  
Phage titration 




), 10µl of helper phage KM13 
was diluted with 90µl 1X PBS buffer. 10 µl of the mixture in the 1
st
 well was taken out 






















) were stretched on agar plate with 10µl/ml Ampicillin or agar plate with 10µg/ml 









) were stretched on agar plate with 10µl/ml Kanamycin. The plates were put in the 
37˚C room.  The number of colonies in each 10µl portion was counted for calculating 
the titer according to the Table 2 shown below. 
 
Table 1. The related values for 10-fold serial dilutions. 100µl of E. coli strain ER2738 was added after the 







































PBS 90µl 90µl … 90µl 90µl 90µl 90µl 90µl 90µl 
 + 
E.coli 100µl 100µl … 100µl 100µl 100µl 100µl 100µl 100µl 
 
Table 2. Calculation of titer according to the plaque numbers in each 10µl portion. The plaques numbers 
were counted after overnight cultivation at 37˚C. The titer (pfu/ml) was calculated with the plaque num-















Volume for titration 10µl  10µl  10µl  10µl  10µl  10µl  































3.2.3 Phage particle preparation 
The pAffi-100-ZWT-Tryp phage stock and pAffi-100-ZHer2:342-Tryp phage stocks were 
prepared separately. For the phage produce, the selected colony with pAffi-100-ZWT-
Tryp or pAffi-100-ZHer2:342-Tryp vector was inoculated and cultivated in TSB+Y medi-
um with 100 µg/ml Amp, 10µg/ml Tet. The overnight culture was re-inoculated into 
100 ml TSB medium with 2% (w/v) Glucose, 100 µg/ml Amp, 10µg/ml Tet. The initial 
O.D.600 value was below 0.1, and the flasks were shaken at 37℃ with 120rpm. When 
the O.D. reached 0.5-0.8, 10 fold excess of helper phage KM13 was added. The culture 
was left in 37℃ without shaking for 30 minutes, centrifuged with 3500g for 10 minutes. 
The cell pellets were resuspended in 100 ml TSB+Y medium with 100µg/ml Amp, 
25µg/ml Km, 10µg/ml Tet, and 0.1mM IPTG. The cells were cultivated at 30℃ with 
100 rpm for overnight.  
In the second day, the overnight culture was centrifuged at 3500g for 15 
minutes. The supernatant was transferred for PEG/NaCl precipitation. After adding 
equal volume 85% Glycerol, it was saved at -20℃. Also, titration is performed with 
ER2738 on agar plates with 100µg/ml Amp, 25µg/ml Km, 10µg/ml Tet. 
3.2.4 Target protein ENBREL® preparation 
Soluble tumor necrosis factor receptor (p75) fusion protein/Fc Chimera (ENBREL®) 
was used as target in the comparative selection. Affibody ZWT was specifically bound to 
Fc part of ENBREL®, while affibody ZHer2:342 acted as control variant. Also, it served as 
target in the pre-selection for the Naïve Affibody library. 200µl ENBREL® (500µg/ml) 
was biotinylated using EZ-Link TM Sulfo-NHS-LC-biotin (Thermo Fisher Scientific). 
A 20 molar fold excess of biotin was added to the protein solution and incubated at RT 
for 30 minutes. The mixture was injected into Slide-A-Lyzer ® 3.5k Dialysis cassettes 
(Thermo Scientific), and incubated in 1X PBS buffer with rotation at 4℃ overnight. 
The biotinylated target protein immobilized on Dynabeads ® M-280 Streptavidin (Invi-
trogen) was tested. 75 µl Dynabeads ® M-280 Streptavidin was washed with 1X PBST, 
and divided into 3 Eppendorf tubes which marked with Tube 1, Tube 2 and Tube 3.  3µl 
biotin-p75 reagent and 172µl 1X PBST were added to Tube 1. Tube 1 was rotated at RT 
for 30 minutes. Then, the liquid without beads in Tube 1 was removed into Tube 2, and 
Tube 2 was rotated in RT for 30 minutes. The liquid was then removed to Tube 3, and 
rotated for another 30 minutes. At last, the liquid was transferred to a new Eppendorf 
tube Tube 4. All the four tubes were saved for the SDS-PAGE. The SDS-PAGE was 
performed with the Mini-PROTEAN® TGX™ Precast Gels (BIO-RAD) at 4˚C for 




3.2.5 Selections with low pH acid and Trypsin elution 
During the selection, all the Eppendorf tubes were blocked with 1X PBST buffer (1X 
PBS buffer with 0.1% (v/v) Tween) and 5% BSA. Beads were split into 100µl in each 
tube, and washed with 1X PBST 3 times before using as well. The phage particles of 
ZWT and ZHer2:342 were mixed as the ratio 1:10000, and the total volume was 1ml. The 
phage mixture was added to the beads and e-o-e rotated for 30 minutes at RT. The su-
pernatant was transfer to a new tube. Then, 7.5µl biotinylated ENBREL® (500µg/ml) 
was added. After 2 hours e-o-e incubation at RT, anther 100µl beads were added to cap-
ture target protein and phage binders. The mixture was e-o-e incubated for 15 minutes at 
RT. The supernatant was discarded, while the left beads were washed 6 times with 1X 
PBST buffer. The washed beads were divided equally into 2 tubes. One was for Gly-
cine-HCl elution, and the other was for Trypsin elution. In the Glycine-HCl elution, 
500µl 50mM Glycine-HCl (pH2.2) was added for 10 minutes with e-o-e, then 450µl 1X 
PBS and 50µl 1M Tris-HCl (pH8.0) was added. In the Trypsin elution, the Trypsin 
stock solution (10mg/ml) was prepared in Trypsin Buffer (50mM Tris-HCl pH=7.5, and 
1mM CaCl2), and stored at -20˚C. Trypsin solution with 1mg/ml was made from the 
stock before the elution. 200 µl Trypsin (1mg/ml) was added for 15 minutes with e-o-e, 
then 300µl 1X PBS buffer was added. 10 µl of elution product was taken out for titra-
tion on agar plates with 100µg/ml Amp. The rest was dropped to infect ER2738 cell 
cultured in 50 ml TSB+Y medium when the O.D. 600 value was 0.5-0.8. After incuba-
tion at 37℃ without shaking for 30 minutes, the culture was centrifuged 3300g for 15 
minutes. The medium was poured off, and the cell pellets were dissolved in 2ml TSB+Y 
medium and plated on TYE plate. The plates were left at 37 ℃ overnight.  
3.3 Construction of Large Naïve Affibody Library in pAffi-100-
Tryp 
3.3.1 Preparation of library inserts and pAffi-100-Tryp vector 
The complete sequence of the new library oligonucleotide Tri-121-mer (Ella Biotech) 
contains 162 bases, of which 121 bases comprised the Helix1 and Helix2 of Z domain. 
The library was based on the WT scaffold. The codons for Cys and Pro were avoided, 
and all the other amino acids were distributed equally in the 13 random positions. 
Moreover, in Pos.31, only 60% of Ile, 10% of Asp, 10% of His, 10% of Lys, and 10% 
of Tyr were included. The sequence of Tri-121-mer was listed in Appendix.  
In order to amplify the library oligonucleotide Tri-121-mer, the Forward primer 
(5’-GATGAAGCCCTCGAGGTAGACAACAAATTCAACAAAGAA-3; underline: 
the overlap with Tri-121-mer) and Reverse primer (5’-TTAGCTTCTGCTAGCAG 
CAAGTTAGCGCTTTGGCTTGGGTCATC -3’; underline: the overlap with Tri-121-




er, and the stock concentration was 923ng/µl. Before used for PCR, the stock was dilut-
ed 42 times to get the concentration 22ng/µl. In each 50µl volume reaction, there was 
approximately 22ng template Tri-121-mer oligo, 0.5µM Forward primer, 0.5µM Re-
verse primer, 200 µM dNTPs, 1X Phusion HF Buffer (Biolabs® NEW ENGLAND), 
and 1 unit Phusion DNA Polymerase (Biolabs® NEW ENGLAND). Totally, there were 
96 reactions. The program was set as the initial denaturation at 98℃ for 30s, 30 cycles 
of denaturation 98℃/10s, annealing 60℃/30s and extension 72℃/30s, and final exten-
sion at 72℃ for 10 minutes, and holding at 4℃ after completion. PCR product was 
pooled together and purified. Totally, there was approximately 6.5mg of Tri-121-mer 
fragment. The phagemid vectors were prepared from the cells containing pAffi-100-
Tryp by NucleoBond ® Xtra Midi/Maxi.  
Both of the vector pAffi-100-Tryp and extension product Tri-121-mer were di-
gested with XhoI and NheI at 37 ℃. After 4h incubation for pAffi-100-Tryp and 3.5 h 
for Tri-121-mer, the reaction mixtures were deactivated at 65℃ for 30 minutes. Each 
cleavage was purified by gel extraction (QIAquick Gel Extraction Kit). 8.0 µg of Tri-
121-mer insert and 17.9µg of pAffi-100-Tryp vector were subjected to ligation using T4 
DNA ligase in 1.6ml reaction volume. The mixture was incubated at RT for 4 hours, 
and at 4℃ for 3 days.  
The ligation product was extracted by Phenol/Chloroform. Equal volume as liga-
tion reaction of Phenol:Chloroform:isoamylalcohol (25:24:1) was added. After 2 
minutes vortex, the sample was centrifuged at 10,000 g for 5 minutes at 4℃. The aque-
ous (upper) layer was transferred to a new tube. Equal volume of Phenol:Chloroform: 
isoamylalcohol was added. Another 2 minutes vortex was applied, which followed by 5 
minutes centrifuge at 10000g at 4℃. The aqueous layer was collected for ethanol pre-
cipitation. 1/10Vol of 3M sodium acetate (pH5.5) and 2.5Vol of ice cold 95% ethanol 
were added. After a brief vortex, the mixture was incubated at -20℃ for 1 hour and cen-
trifuged at 21500g for 1 hour at 4℃. The supernatant was removed, and 1ml ice-cold 
70% ethanol was added. The mixture was spun briefly. The decant supernatant moved, 
and air dry was applied to the pellet. At last, the pellet was dissolved in 140µl EB buff-
er.    
The concentration of purified ligation was determinate by the transformation ef-
ficiency where 1µl ligation was electro-transformed with 25µl E.coli strain ER2738 
(Lucigen). 1µl ligation product was mixed with 25µl E.coli strain ER2738 and added 
into the Gene Pulser/MicroPulser Cuvette (BIO-RAD) with 0.2cm gap. The transfor-
mation was performed with MicroPulser
TM
 electroporator (BIO-RAD) with 1.8kV and 1 
pulse. After the electro-transformation,  the mixture was immediately removed back to 
Eppendorf tube, and 974µl pre-warmed SOC medium (TSB+Y medium with 5% (w/v) 
glucose, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4) was added. The tube 
was rotated at 37˚C for 1h. 200µl of the culture was transferred to the 1st tube (10-1 tube) 
with 800 µl TSB+Y medium for a tenfold serial dilution. After totally mixed, 200 µl of 
culture from 10
-1




 tube). The 10-fold serial dilu-
tion continued till the 10
-5








for plating on agar plates with 100µg/ml Amp and 10µg/ml Tet. The plates were kept in 
37˚C overnight. The colonies were counted in the second day. The transformation effi-
ciency was approximately 1.28×10
8
 colonies per shoot.  
3.3.2 Electro-transformation with E. coli strain ER2738 
The ligation products were electro-transformed into E. coli strain ER2738 (Lucigen). 
2µl of extract was mixed with 25µl of E. coli, and added into the Gene Puls-
er/MicroPulser Cuvette (BIO-RAD) with 0.1cm gap. The instrument MicroPulser
TM
 
electroporator (BIO-RAD) was used, and the preset conditions were set as 1.8kV with 1 
pulse. After each electro-transformation, the mixture was immediately removed back to 
Eppendorf tube, and 875µl pre-warmed Recovery Medium (Lucigen) was added. Then, 
the cells and medium were transferred to a 15ml Falcon tube. Every 7 or 8 transfor-
mations were pooled together. Total 31 electro-transformations were made, and mixed 
into 4 pools for overnight cultivation. Each pool mixture was left in 1L TSB+Y medium 
with 100 µg/ml Amp and 10µg/ml Tet.  
Titration was done after 1 hour incubation and before pouring into big overnight 
cultivation. 100µl culture was taken out from each flask, and a 10-fold serial dilution 




 tube), 100µl culture was mixed with 900µl TSB+Y 
medium. After well mixed, 100µl culture from 10
-1





 tube). The 10-fold serial dilution continued till the 10
-7
 tube. 100 µl of culture was 









 tubes was poured back to the flasks. The plates were kept in 37˚C 
overnight. The flasks were shaken at 37℃ with 120rpm. After overnight cultivation, 
O.D. 600 of each pool was measured in order to calculate the copy of each pool. Four 
pools were mixed together with the same copy number. The cells were harvested by 
centrifuge 7 minutes at 4000g. Then, the pellets were dissolved in 40% Glycerol. The 
library cell pellets were split equally into 4ml in 15ml Falcon tube, and total was 8 
tubes. These Falcon tubes were stored at -70 ℃. 
3.3.3 Helper phage and phage particle preparation 
More helper phage particle was prepared. The steps were similar to the one mentioned 
in the section 3.2.3. The cultivation (TSB+Y medium with 25µg/ml Km, and 10µg/ml 
Tet) volume increased to 2L. 4ml of library cell was inoculated into 6L TSB medium 
with 2% (w/v) Glucose, 100µg/ml Amp, 10µg/ml Tet. The initial O.D.600 was below 
0.1, and the flasks were shaken at 37℃ with 120rpm. When the O.D. reached 0.5-0.8, 
10 fold excess of helper phage KM13 (6.9×10
12
 pfu/ml) was added. The culture was left 
in 37℃ without shaking for 30 minutes, and then was centrifuged with 3500g for 10 
minutes. The cell pellets were resuspended in 6L TSB+Y medium with 100µg/ml Amp, 
25µg/ml Km, 10µg/ml Tet, and 0.1mM IPTG. The cells were cultivated at 30℃ with 




harvest the phage. The supernatant was transferred for PEG/NaCl precipitation which 
was mentioned in Section 3.2.2. The collected phage particle was titrated with E. coli 
ER2738 on agar plates with 100µg/ml Amp. The phage particles were stored in 4˚C. 
3.3.4 Sequencing of cell library and phage library 
96 colonies were sequenced from cell library and phage library to check the 18 amino 
acids distribution in randomization positions. For the cell library, 96 single colonies 
were randomly picked up from the titration plates. For the phage library, phage particle 
was added into E. coli strain ER2738 cultivation when the O.D. value is between 0.5-
0.8. After 30 minutes incubation at 37˚C without shaking, 1 ml of the mixture was taken 
out for series dilutions and spread on agar plates with 100µg/ml Amp. The plates were 
put at 37˚C overnight. One the second day, 96 single colonies were randomly picked up. 
PA-PCR was performed as Section 3.1.2. RIT27 and DOLI2 were chosen as forward 
and reverse primers. In the Cy-seq PCR, primers pAffi-100-For (5’-CACACAGGA 
AACAGCTATGACCATG-3’) and ABD-Rev (5’-CTATCAGTGCTTTTACACCTTC 
AACAG-3’) were used. The program was changed with initial denaturation at 98℃ for 
30s, 30 cycles of denaturation 98℃/10s, annealing 62℃/30s, and extension 72℃/30s, 
and final extension at 72℃ for 10 minutes, and holding at 4℃ after completion.  After 
ethanol precipitate, Cy-seq PCR product was dissolved in Milli-Q and sent for sequenc-
ing.  
3.4 Selection to target protein rhEphrin-B3  
3.4.1 Target protein rhEphrin-B3 Preparation 
Recombinant Human Ephrin-B3/Fc Chimer (rhEhprin B3, R&D systems) was chosen as 
target in the Naïve Affibody library selection. 1ml rhEphrin-B3/Fc Chimera with the 
concentration 100µg/ml was biotinylated using EZ-Link TM Sulfo-NHS-LC-biotin 
(Thermo Fisher Scientific). A 20 molar fold excess of biotin was added to the protein 
solution. The mixture was injected into Slide-A-Lyzer® 2K Dialysis Cassettes (Thermo 
Scientific), and incubated in 1XPBS buffer with rotation at 4℃ overnight. The test for 
the amount of target immobilized on Dynabeads ® M-280 Streptavidin (Invitrogen) was 
prepared, which was determined by SDS-PAGE.   
3.4.2 Selection with low pH acid and Trypsin elution 
The selection was performed essentially as described in Section 3.2.5 with some modi-
fications. A pre-selection to ENBREL® was made before the selection to target protein 




In Round 1, two tubes with 1 ml/tube naïve phage library (1.8×10
10
 cfu/ml) were 
used for selections. In the pre-selection, 15µl biotinylated ENBREL® (500µg/ml) was 
added in each tube. After 1h e-o-e incubation at RT, 100µl beads were added to capture 
ENBREL® and phage binders. The mixture was e-o-e incubated for 15 minutes at RT. 
The supernatant was removed and equally divided into new blocked Eppendoff tube 
marked with Tube 1 and Tube 2. Then, 50µl bio-Ephrin-B3 was added into Tube 1, 
while 50µl bio-Ephrin-B3 and 10µl Ephrin-A2 were added into Tube 2. The mixtures 
were incubated at RT for 2h, and transferred to new blocked tubes with 125µl pre-
wahsed beads. The mixture was e-o-e rotated for 15 minutes at RT. The supernatant was 
discarded, and the beads were washed 3 times with 1X PBST. Tube 1 was divided into 
Track 1 and Track 2, while Tube 2 was divided into Track 3 and Track 4. Track 1 and 
Track 3 were eluted with Glycine-HCl, while Track 2 and Track 4 were eluted with 
Trypsin. In the Glycine-HCl elution, 500 µl 50mM Glycine-HCl (pH2.2) was added for 
10 minutes with e-o-e, then 450 µl 1X PBS buffer and 50µl 1M Tris-HCl (pH8.0) was 
added. In the Trypsin elution, 200 µl Trypsin (1mg/ml) was added for 15 minutes with 
e-o-e, then 800 µl 1X PBS buffer was added. 10 µl of elution product from each track 
was taken out for titration on Amp plates. The rest 990 µl was dropped to infect 200 ml 
ER2738 cell when the O.D.600 value was around 0.5-0.8. After incubation at 37℃ 
without shaking for 30 minutes, the culture was centrifuged 3300g for 15 minutes. The 
medium was poured off, and the cell pellets were dissolved and plated on TYE plate. 
The plates were left at 37 ℃ overnight.  
In the second day, the colonies were scraped off with TSB medium. A portion of 
the scraped cell suspensions was diluted to measure the O.D.600 value. For phage parti-
cle produce, the scraped cell suspensions were inoculated in 200ml TSB medium (2% 
(w/v) glucose, 100µg/ml Amp and 10µg/ml Tet), where the initial O.D600 value was 
0.1. The flasks were shaken at 37˚C with 150 rpm. The following steps were the same 
as the section 3.2.3 to prepare the phage particles.   
From Round 2 to Round 4, the final concentration of rhEphrin-B3 was decreased 
which was 50nM in Round 2, 10nM in Round3, and 5nM in Round4. The parameters 
for each selection were shown in Table 3. In the Round 4, the elution products were 
saved without infecting E. coli to produce phage particle.  
After overnight cultivation of cells infected by the elute from Round 4 on agar 
plates with 100µg/ml Amp, 48 colonies were randomly picked from each track for se-
quencing. The steps and programs were the same with the ones for sequencing the li-
brary which were mentioned in Section 3.3.4. The following work including analysis of 









Table 3. An overview of the selection parameters. There were four tracks performed. Track 1 and Track 3 
were eluted by Glycine (pH2.2), and Track 2 and Track 4 were eluted by Trypsin. The concentration of 







Round 1 100 nM 
100 nM 
3 × washes 
Glycine (pH 2.2) 10 minutes 
Trypsin 25 minutes 
Round 2 100 nM 
50 nM 
5 × washes 
Glycine (pH 2.2) 10 minutes 
Trypsin 25 minutes 
Round 3 50 nM 
10 nM 
8 × washes 
Glycine (pH 2.2) 10 minutes 
Trypsin 25 minutes 
Round 4 33 nM 
1 nM 
10 × washes 
Glycine (pH 2.2) 10 minutes 






4. RESULTS  
4.1 Phage display system design  
Sequencing of g3p in phagemid pAffi-100-Tryp 
The phagemid vector called pAffi-100-Tryp was constructed from pAffi-1. The full-
length g3p took the place of truncated g3p (D3), and a trypsin-sensitive linker was in-
troduced between library member and p3 in the resulting vector. The sequencing results 
of g3p were checked and compared the III attachment protein [Enterobacteria phage 
M13] in NCBI (Shown in Appendix) (http://www.ncbi.nlm.nih.gov/gene/?term=m13 
+pIII). However, there were some mutations in g3p which listed in Table 4. Totally, 
there were eight mutation positions in DNA level, which influenced seven amino acids. 
Four out of seven were synonymous mutations, which did not make amino acid change. 
P11S was located in the N1 domain, P198L was in the N2 domain, and S360G was in 
the CT domain. However, the mutations did not prevent phage particles to infect E.coli 
cells.  
 
Table 4. DNA mutations and amino acid change in the phagemid pAffi-100-Tryp  
Position 10 11 35 198 199 360 368 
G3p in NCBI AAA→L CCC→P GGT→G CCA→P TTC→F AGC→S TCT→S 
G3p sequenced AAG→L TCC→S GGC→G TTA→L TTT→F GGC→G TCA→S 
Comparative selection by low pH elution and Trypsin elution 
In the comparative test selection, either ZWT gene or a control variant ZHer2:342 was in-
serted in the place of Dummy to get the phagemid pAffi-100-ZWT-Tryp and pAffi-100-
ZHer2:342-Tryp. After the electro-transformation into E. coli strain ER2738, the cells har-
boring pAffi-100-ZWT-Tryp and pAffi-100-ZHer2:342-Tryp were gained. With the helper 
phage KM13, the phage particles with ZWT and ZHer2:342 type Affibody were produced. 
The titer for ZWT phage particle on agar plate with 100µg/ml Ampicillin was 
9.2×10
10
cfu/ml, while it was 2.2×10
10
cfu/ml for ZHer3:242 phage particle.  
The phage mixture was prepared by ZWT phage particle and ZHer2:342  phage par-
ticle as the ratio 1: 10000, and the amount of ZWT phage particle was 2.0×10
6
 cfu. After 
the selection, the amount of phage particle from Glycine elution was 1.2×10
5 
cfu (6%), 
while it was 9.2×10
4




picked for sequencing. There were 84 readable sequences from Glycine elution and 96 
readable sequences from Trypsin elution. All the sequences both in Glycine elution and 
Trypsin elution were ZWT. It showed that the new phagemid pAffi-100-Tryp worked, 
and both low-pH acid and Trypsin were possible to elute the phage after the selection.  
4.2 Protein preparation 
Both of ENBREL® and rhEphrin-B3/Fc Chimera were biotinylated with biotin reagent 
in a molar excess of 20:1. The minimal amount of streptavidin coated beads possible to 
bind to 3.75µg ENBREL® and 5µg rhEphrin-B3/Fc Chimera was determined. With the 
binding assay, 100µl beads were needed for 3.75µg ENBREL®, while 125µl beads 
were needed for 5µg rhEphrin-B3/Fc Chimera 
The results about the binding assay of rhEphrin-B3 were shown in Figure 10. 
There was no much difference between the molecular weight before and after dialysis. 
In the binding assay, there were 3 tubes each containing 25µl streptavidin coated beads 
used. The rhEphrin-B3 was only found in 1
st
 tube. Therefore, all rhEphrin-B3 was able 
to bind to beads in the 1
st




 one. In anoth-




Figure 10. Binding assay with SDS-PAGE. From left to right, the sample in each lane was 1) Low mo-
lecular weight (LMW) ladder, 2) rhEphrin-B3 before dialysis, 3) rhEphrin-B3 after dialysis 4) 1
st
 tube in 
binding assay 5) 2
nd
 tube in biding assay. 6) 3
rd
 tube in binding assay. 


























4.3 Cell library and phage library  
The cell library was constructed by 31 electro-transformations. The size of cell library 
was 4.7×10
9
 cfu. The cells were harvested and concentrated into 23.5ml, and the copy 
number was approximately 32 in 1ml. The sequencing results of library from 2×96 
wells plates were summarized (Figure 11): 1) There were 140 readable sequences out of 
192 samples; 2) 31 clones contained insertion or deletion, 1 clone contained mutation, 
and 1 clone contained Dummy. 3) 6 clones had Proline. 4) Therefore, the number of 
functional clones was 107, and the percentage of functional clones was 76.4%. The 
amino acid distribution in the randomization positions from the 107 functional clones 
was shown in Figure 6. In the Position 10, 11, 14, 24, 28, 32, Proline was found. The 
range of each amino acid percentage was from 1% to 15%, excluding in the Pos. 31. 
There was 61% Ile, 7% Lys, 10% Tyr, 11% His, and 12% Asp in the Pos. 31. 
 
Figure 11. Amino acid distribution in 14 randomization from 107 functional clones. The distribution was 
shown in percentage. The theoretical value was about 5.56% for each amino acid in each position exclud-




4.4 Selection to rhEphrin-B3/Fc Chimera 
The four round selections were performed with a pre-selection to ENBREL® in each 
round. In order to increase selection stringency, the number of washes was increased for 
each additional round and the target concentration was decreased. A figure about the 
enrichment from Round 2 to Round 4 was made (Figure7). There was obvious enrich-
ment after Round 3 selection for Glycine (pH=2.2) elution, while it was Round 2 for 
Trypsin elution. 
After four round selections, 48 clones were randomly picked from each track for 
candidates sequencing. The amino acids in the randomization positions in readable 
clones were given in the table 5.2. In all the four tracks, ZWT was found after Round 4 
selection. In Track 1, 2, and 3, clones harboring the phagemid expressing ZWT occupied 
more than 64%. However, it was possible to get repeat clones in each track, which 
meant that the repeated clones might be potential binders to rhEphrin-B3. The sequenc-




Figure 12. Phagemid enrichment from Round 2 to Round 4 in each Track. Track 1 and Track 3 were 


































The binding properties of the selected Affibody were measured with Biacore. The 
clones with highest repeats in each track excluding ZWT were chosen for Biacore meas-
urements. The protein rhEphrin-B3/Fc Chimera and p75-Fc (ENBREL®) as a negative 
control were immobilized on chip. As shown in Figure 13, all the candidates were only 
able to bind to rhEphrin-B3/Fc, and none was able to bind to p75-Fc. Therefore, the 
binding sites of rhEphrin-B3/Fc were not Fc part, and the candidates were real binders 
to rhEphrin-B3.  The candidate from Track 4 (T4) had the greatest response which was 
more than 50 resonance units (RU). The responses for candidate from Track 1 and can-
didate from Track 2 were quite similar, which were only about 10 RU. Moreover, the 
candidate from T4 had a very slow off rate. 
 
 
Figure 13. Biacore sensorgram. Four different Affibody molecules from selected clones were injected 









































































Biacore results of Fc-EphrinB3 binders 











































































Biacore results of Fc-EphrinB3 binder 









Table .5 Sequencing results of picked clones in each track. 
Position  10     20    30         40           50  
  ↓     ↓        ↓    ↓            ↓  
Zwt VDNKFNKE QQN A FY EI LH LPNLN EE Q RN AF IQ SL K DDPSQSANLLAEAKKLNDAQAPK Repeat 
Track 1 
+ 35 Zwt 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ QEV – LT – – LD ‒ ‒ ‒ ‒ ‒ HE – MM – – IS ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 8 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ MDQ – MD – – MK ‒ ‒ ‒ ‒ ‒ HE  – VM – – IH ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 2 
Track 3 




‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ REI – WW – – VQ ‒ ‒ ‒ ‒ ‒ HA – VQ – – IE ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 6 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ AHE – WW – – VD ‒ ‒ ‒ ‒ ‒ ST – VA – – IL ‒ ‒ H ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 3 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ WEM – MK – – KE ‒ ‒ ‒ ‒ ‒ ST – HY – – II ‒ ‒ Y ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ FEA – FI – – FG ‒ ‒ ‒ ‒ ‒ HD – EM – – IA ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ WEF – YE – – RL ‒ ‒ ‒ ‒ ‒ HE – AM – – IK ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ HQM – YE – – YH ‒ ‒ ‒ ‒ ‒ HM – MN – – IH ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
Track 2 
+ 28 Zwt 
  
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ VDA – FE – – LG ‒ ‒ ‒ ‒ ‒ HE – VQ – – IH ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 11 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ FEQ – YA – – FT ‒ ‒ ‒ ‒ ‒ HI – EM – – IH ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 2 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ RDH – YN – – SS ‒ ‒ ‒ ‒ ‒ HE – AM – – IS ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ QEQ – YL – – SS ‒ ‒ ‒ ‒ ‒ HG – VQ – – IH ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 
Track 4 
+ 3 Zwt 
  
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ RDM – YL – – LD ‒ ‒ ‒ ‒ ‒ HS – VY – – IA ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 36 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ RQK – YY – – MA ‒ ‒ ‒ ‒ ‒ HA – VI – – IN ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 2 
‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ FER – YL – – FN ‒ ‒ ‒ ‒ ‒ HK – EM – – IY ‒ ‒ W ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 1 







5.1 Design of a phage library project 
Generally, there are three stages for performing display selection from a library: 1) cre-
ating a library of (poly)peptide variants; 2)selection; and 3) analysis of the selected 
clones (Russel et al., 2004). The flow diagram illustrating a phage display project is 
shown in Figure 14.  
 
 
Figure 14. Flow diagram of doing a phage display project. At first, the vector is constructed, and the 
display system is confirmed. Then, the real Naïve library is built. After several rounds selection, selected 
clones are analysed. (Adapt from Russel et al., 2004) 
 
In this work, the first stage is to construct a phagemid vector pAffi-100-Tryp and 
confirm the functional display of ZWT and ZHer2:342. The target combinatorial library has 
the cell size 4.7×109 cfu which is achieved by randomization in 14 positions.  
The variability of the library can be achieved by several methods. An equimolar 




domized oligonucleotide sequence. However, 3 stop codons (TAA, TAG, and TGA) are 
possible to locate in the randomized position and induce prevention of the biosynthesis 
of the coat protein. An improved method is used where a mixture of guanine and thy-
mine or guanine and cytosine are incorporated in position three of the codons. Two stop 
codons TAA and TGA are eliminated in this method. The remaining TAG can also be 
suppressed in a supE E. coli strain (Bossi, 1983). NN(G/T) degenerate codons are used 
for Affibody molecule library Zlib-1 and Zib2002 (Nord et al., 1995; Grönwall et al., 
2007). They include 32 codons in total for all 20 amino acids.  However, the best meth-
od to introduce variety in a library is the trinucleotide approach which was used in this 
research (Kayushin et al., 1996). This approach eliminates the integration of stop and 
rare codons, which avoids some translational problems such as frame shifting (Belcourt 
and Farabaugh, 1990).  
In some cases, it was possible to order appropriate pre-made phage display li-
brary, which are commercially available, to construct the phage library, such as 
Ph.D.™-12 Phage Display Peptide Library from New England Biolabs. The dodecapep-
tide (Ph.D-12) library has the complexities on the order of 10
9
 independent clones. 
However, there is still no commercial Affibody molecule phage library. One quite use-
ful Affibody molecule is Zlib2002 which was designed by Grönwall (Grönwall et al., 
2007). The new designed was based on the trinucleotide approach, and a protease sensi-
tive site was introduced. The new Affibody molecule library with these improvements 
has the potential to become a promising tool for highly stringent binder selections.  
The most common approach to select desired clones is through an in vitro bind-
ing incubation (Russel et al., 2004). The members from phage library bind to a target. 
After washing, the retained phages are eluted. The process is also called biopanning. 
The eluted phages are used to re-infect E. coli for amplification, and several more strin-
gent selections are performed. Generally, same sequencing fragment can be observed 
after three rounds selection. The first round of selection is considered the most im-
portant one, because any bias or loss of diversity will be amplified in the following 
rounds. The targets can be immobilized on streptavidin beads which was the approach 
used in this research. Furthermore, the targets can be adsorbed to plastic, and captured 
to agarose or plates (Christ, 2009). The enrichment of target specific phage is achieved 
by binding to immobilized target. After the selection, the eluted phage titrated and re-
infected E. coli. New produced phage is isolated and purified for subsequent rounds of 
selection. After the third round selection, the individual colonies can be picked for bind-
ing affinity test. The fourth round selection with harsh conditions is performed to obtain 
binders with higher affinity. The enrichment of individual clones is also an indicator to 
monitor the selection process. Relative high enrichment means most of the phage parti-
cles before selection are able to bind to the immobilized targets. Therefore, relative low 
enrichment in the first two rounds and high enrichment in the third and fourth rounds 
may indicate a successful selection.  
After three or four rounds of selection, the eluted phages and random clones are 




ty of the picked clones is sequencing. The binders with high repeat potentially have 
great binding properties to the targets. The candidate binders are selected for measuring 
the Affibody molecules properties. Biacore is one of the most popular biosensor on the 
interactions between proteins and other molecules. This technology is based on the la-
bel-free SPR which enables real-time detection monitoring of biological molecular 
events and provides quantitative information (Laure et al., 2001). ELISA is also a wide-
ly used approach to monitor the affinity of Affibody against the target (Bobrovnik, 
2003). The binding properties are confirmed for future work.   
5.2 Phagemid with full-length g3p and helper phage KM13 
In this work, new phagemid was designed with full-length g3p. In previous researches, 
the low display efficiency is often observed with the conventional M13KO7 helper 
phage. The majority of progeny phage particles contain wild-type pIII which from help-
er phage, which causes high background of non-displaying phage which cannot partici-
pate in affinity selection (Bratkovič, 2010).  Helper phage KM13 is used to reduce the 
background during the selection and the inactivated by trypsin. Helper phage KM13 is 
protease sensitive. This modified helper phage contains a modified g3p which encodes a 
trypsin cleavage site between D2 and D3. Therefore, after treated with trypsin solution, 
helper phage KM13 loses the ability to infect E. coli (Kristensen and Winter, 1998; 
Gotez et al., 2002). 
Full-length g3p is essential in phagemid vector, when helper phage KM13 is 
used. If the phage particles are produced from phagemid vector containing full-length 
g3p and helper phage KM13, the coat protein pIII is either full-length pIII with dis-
played desired Affibody molecule or full-length pIII without Affibody molecule. The 
pIII with Affibody molecule is originated from the constructed phagemid vector, and 
the Affibody molecule can be cleaved off from pIII with trypsin. On the other hand, the 
pIII without Affibody molecule is due to the helper phage KM13, and there exists a 
trypsin site between the D2 and D3 of pIII. With the treatment of trypsin solution, the 
pIII loses its infectivity on E. coli. Therefore, after treated with trypsin solution, the 
produced phage particle is only infective when it possesses pIII with displayed Affibody 
molecule. When truncated g3p is used instead of full-length g3p, the produced phage 
particles contain truncated pIII with Affibody molecule (from constructed phagemid 
vector) and full-length pIII without Affibody molecule (from helper phage KM13). 
However, with the treatment of trypsin, all the pIII only have D3 which means the 
phage particle is not infective. In the system of phagemid vector and KM13, high excess 
wild-type pIII is also expressed. However, it can be cleaved to lose all their domains D1 
and D2 of pIII, thus the phage particles lose the ability to infect bacteria. The phage 
particle carrying the pIII from phagemid pAffi-100-Zlib-Tryp would retain their infec-
tivity.  
The helper phage KM13 has been well studies for antibody fragment produce. It 




tion with trypsin treatment compared to other conventional methods. A large variety of 
antiidiotypic antibodies (Ab2s) are first time generated after only two or three rounds of 
selection (Goletz et al., 2002). Furthermore, helper phage KM13 was used in construct-
ing a compact phage display human scFv library. Good results were observed when 
using KM13 compared with regular helper phage M13KO7 (Pansri et al., 2009).  
5.3 Library quality 
Library quality is a key factor to get clones with desired properties. A library with insuf-
ficient size, poor or inappropriate diversity, or failed design is unlikely to get success. A 
highly diverse library is a good start for the selection. Also, it is necessary to check if 
the cloned genes are efficiently displayed on the phage capsid. Generally, the higher 
diversity of a library enables the higher possibility to attain high affinity binders.  
The quality of an initial DNA-library is normally evaluated by it diversity. Be-
cause there are 20 different natural amino acids, in theory the number of different pep-
tide sequences obtained by randomization of N residues can reach 20
N
. If the number of 
random positions is 13, it is possible to get almost 1×10
17
 individual sequences. If one 
more random position is added, the number of obtained individual sequences can get 20 
times amplified which is about 20×10
18
. Although there were 14 positions randomized 
in this research, 18 different amino acids without Cys and Pro were distributed equally 
in the first 13 random positions. Moreover, in the last random position only Ile, Asp, 




Generally, there are two factors limits the generation of different phage clones 
(library size). One is the amount of phage-encoding DNA molecules generated in vitro. 
The other one is the transformation efficiency of the DNA molecules into E. coli. It is 
considered that only 1% of the DNA molecule transferred into E. coli by electro-
transformation. Several hundred µg of DNA are often required to obtain 10
9
 trans-
formants. Therefore, in this experiment, the efficiency of transforming the pAffi-100-
Zlib-Tryp into the ER2738 cell may limit the Affibody diversity. In order to increase the 
efficiency in each transformation, it is possible to choose the competent cell with good 
quality. Also, the size of the library size can be improved by increasing transformation 
times. Not all the clones display with similar efficiency. Some sequences are hard to 
display which causes underrepresentation in the phage library level. For an instance, 
cysteine is avoided in the new library, and the reason that the formation of inappropriate 
disulfide bonds can cause rare express as expected (Russel et al., 2004).  
A frequently used Affibody molecule phage library Zlib2002 contains 3×10
9
. It 
was described by Grönwall (Grönwall et al., 2007). 13 positions in the Z domain (ZWT) 
were chosen for randomization through the NNG/T degeneracy. They were Q9, Q10, 
N11, F13, Y14, L17, H18, E24, E25, R27, N28, Q32 and K35. The Z domain-encoding 
DNA sequence with mutagenesis was inserted into phagemid vector pUC119, which 




for 46 amino acid ABD and gene for the residues 249-406 of M13 phage coat protein III 
(g3p). In the end, the library Zlib2002 was generated by repeated electro-transformation 
with E. coli. The new library was designed based on the inspiration from Zlib2002. In 
my research, the mutations were introduced by trinucleotide approach. In the new con-
structed phagemid vector pAffi-100-Tryp, a full-length g3p took the place of the trun-
cated one in phagemid pAffi1. Furthermore, phagemid pAffi-100-Tryp contained a 
trypsin sensitive site. The new library was also obtained through multi-transformation 
by electroporation. The size of the library was demonstrated to have 4.7×10
9
 members 
after titration.  
The distribution of each amino acid in every random position is an important 
factor to affect the library quality. After transformation, the phagemids from individual 
bacterial colonies are extracted for DNA sequencing. The frequency of appearance of 
each amino acid in the random position is calculated by analysis of the corresponding 
codon. In order to analysis the amino acid distribution of one library, at least 50-100 
clones should be sequenced. In this research, 96 of clones originated from the trans-
formed E. coli cell library stock and 96 of clones infected by the phage from prepared 
Affibody molecule phage library were randomly picked to determine the nucleotide 
diversity and frequency of the amino acid. However, sometimes it was impossible to 
analyze all the randomization position in the sequencing result from the first 96 samples. 
The reason might be that several phagemids entered the same cell during transformation. 
Therefore, prepared phage library enabled a better sequencing result.  
5.4 Selection and post-selection analysis 
Several parameters can influence the fate of affinity selection. The selection conditions 
were designed to obtain binders with high stringency. In the first round, the selection 
condition was performed to get the binders with lower stringency. Then, it is gradually 
intensified for higher stringency in the following selection rounds. For example, the 
target rhEphrin B3 concentration was decreased from 100nM to 1nM, where less targets 
available for phage binding leaded to higher stringency. Also, the washing times during 
the selection were increased from 3 to 10.  
Furthermore, the number of phage copies of the initial phage library should be 
considered. Non-linear propagation of the individual clones clearly causes a significant 
bias in the selection procedures. Less than 1% of Affibody molecule from the initial 
library is expected to bind to target with specific binding in an idealized panning exper-
iment. However, due to the unspecific interactions, phages can also be attached to the 
target with non-binding or unspecific binding. Though the non-binding phage can be 
eliminated under harsh washing condition, the unspecific binder might still exist. After 
the elution step, if the specific binders are present in a low number of copies and propa-
gate slowly, they may have weak competence to outgrow compared to the unspecific 
binder. Therefore, a pre-selection was performed to overcome this problem. The unspe-




Elution condition is another important parameter affecting the outcome of affini-
ty selection.  The wildly accepted non-specific elution is using buffer 0.2 M Glycine-
HCl (pH 2.2). The release achieved by weakening the peptide-target interaction instead 
of destroying phage infectivity. However, it is unable to break some interactions where 
binders having great affinity. The trypsin digestion used in this work has been reported 
as a favorable method for releasing affinity-selected virions from immobilized selectors 
(Thomas and Smith, 2010).  
As shown in the sequencing result of Table 5, some similar patterns were found 
among the binders. Interestingly, only Ile was found in Pos.31 in all the sequenced 
phagemid. Pos.31 is considered as a core position in the interaction between the Af-
fibody molecule and target. In the Pos.31 randomization design, several kinds of amino 
acids were chosen to vary the properties of engineered Affibody molecules. Ile is pre-
sent in the ZWT residue; Asp is with negative charge; Lys is with positive; His switches 
at pH5.5; Tyr is often included in antibody-antigen interaction surfaces.   
However, quite high amount of phages display ZWT was observed (Figure 5). 
The contamination was suggested due to the pre-selection system where ENBREL® 
was used. Because ENBREL® is a ZWT specific protein, Affibody molecule ZWT was 
bound to biotinylated ENBREL® in the pre-selection. Though the complex Affibody 
molecule and ENBREL® was immobilized on the beads with streptavidin, it was still 
possible to transfer beads with ZWT-displaying phage into a new Eppendorf tube for the 
selection against rhEphrin-B3. The phage particles displaying ZWT was eluted off with 
other phage expressing specific Affibody molecule for rhEphrin-B3. Since the pre-
selection was performed in each round before the selection against rhEphrin-B3, the 
enrichment of ZWT displaying phage could result in a high repeat shown in the sequenc-
ing result. Altering the target protein in different selection rounds or using other immo-
bilization method instead of the interaction between EZ-Link TM Sulfo-NHS-LC-biotin 
and Dynabeads ® M-280 Streptavidin will be helpful to decrease the bias.  
Biacore results showed several most promising Affibody molecule was from 
Track 4 (Figure 8). However, it only showed the specificity analysis due to the time 
restriction. In order to determine the affinity, dissociation constant Kd should be meas-
ured in further researches. Kinetic analysis is also necessary to study the binding proper-





6. SUMMARY AND FUTURE WORK 
In this project, a new Affibody library has been constructed for highly stringent binder 
selections. The size of the library is approximately 4.7×10
9
 cfu, and there were 76% 
functional clones in the library. In the selection to rhEphrin-B3, the bound phage was 
able to be cleaved by trypsin, and reinfect. After four rounds selection, candidate bind-
ers were selected. According to the sequencing results, there were similar patterns 
among the candidate binders. Also, only Ile was found in Position 31.  
In the future work, more protein needs to be expressed. With the sufficient 
amounts of proteins, the affinity of promising binder will be measured. Since rhEphrin-
B3 is involved in the interactions with Eph receptors, the Affibody binding to rhEphrin-
B3 but not Eph receptors can be selected. Furthermore, this is a cooperative project with 







Ahlgren, S., Orlova, A., Wallberg, H., Hansson, M., Sandstrom, M., Lewsley, R., 
Wennborg, A., Abrahmsen, L., Tolmachev, V. & Feldwisch, J. 2010, "Targeting of 
HER2-expressing tumors using 111In-ABY-025, a second-generation affibody 
molecule with a fundamentally reengineered scaffold", Journal of nuclear medicine 
: official publication, Society of Nuclear Medicine, vol. 51, no. 7, pp. 1131-1138.  
Alberts, B. 2008, Molecular Biology of the Cell: DVD-ROM, Garland Science.  
Arora, P., Oas, T.G. & Myers, J.K. 2004, "Fast and faster: A designed variant of the B-
domain of protein A folds in 3 µsec", Protein Science, vol. 13, no. 4, pp. 847-853.  
Barbas, C.F., Burton, D.R., Scott, J.K. & Silverman, G.J. 2004, Phage Display: A La-
boratory Manual, Cold Spring Harbor Laboratory Press.  
Baum, R.P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolma-
chev, V. & Feldwisch, J. 2010, Molecular Imaging of HER2-Expressing Malignant 
Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Af-
fibody Molecules.  
Belcourt, M.F. & Farabaugh, P.J. 1990, "Ribosomal frameshifting in the yeast re-
trotransposon Ty: tRNAs induce slippage on a 7 nucleotide minimal site", Cell, vol. 
62, no. 2, pp. 339-352.  
Berova, N., Nakanishi, K. & Woody, R. 2000, Circular Dichroism: Principles and Ap-
plications, Wiley.  
Berthier, J. & Silberzan, P. 2010, Microfluidics for Biotechnology, Artech House.  
Beuttler, J., Rothdiener, M., Müller, D., Frejd, F.Y. & Kontermann, R.E. 2009, "Target-
ing of Epidermal Growth Factor Receptor (EGFR)-Expressing Tumor Cells with 
Sterically Stabilized Affibody Liposomes (SAL)", Bioconjugate chemistry, vol. 20, 
no. 6, pp. 1201-1208.  
Bingle, W.H., Nomellini, J.F. & Smit, J. 1997, "Linker mutagenesis of the Caulobacter 
crescentus S-layer protein: toward a definition of an N-terminal anchoring region 
and a C-terminal secretion signal and the potential for heterologous protein secre-
tion.", Journal of Bacteriology, vol. 179, no. 3, pp. 601-611.  
Bobrovnik, S.A. 2003, "Determination of antibody affinity by ELISA. Theory", Journal 




Boder, E.T., Midelfort, K.S. & Wittrup, K.D. 2000, "Directed evolution of antibody 
fragments with monovalent femtomolar antigen-binding affinity", Proceedings of 
the National Academy of Sciences, vol. 97, no. 20, pp. 10701-10705.  
Boder, E.T. & Wittrup, K.D. 1997, "Yeast surface display for screening combinatorial 
polypeptide libraries", Nat Biotech, vol. 15, no. 6, pp. 553-557.  
Bossi, L. 1983, "Context effects: translation of UAG codon by suppressor tRNA is af-
fected by the sequence following UAG in the message", Journal of Molecular Bi-
ology, vol. 164, no. 1, pp. 73-87.  
Bostrom, J., S. F. Yu, D. Kan, B. A. Appleton, C. V. Lee, K. Billeci, W. Man, et al. 
2009. Variants of the antibody herceptin that interact with HER2 and VEGF at the 
antigen binding site. Science (New York, N.Y.) 323 (5921) (Mar 20): 1610-4. 
Bowley, D.R., Labrijn, A.F., Zwick, M.B. & Burton, D.R. 2007, "Antigen selection 
from an HIV-1 immune antibody library displayed on yeast yields many novel an-
tibodies compared to selection from the same library displayed on phage", Protein 
engineering, design & selection : PEDS, vol. 20, no. 2, pp. 81-90.  
Bradbury, A.R. & Marks, J.D. 2004, "Antibodies from phage antibody libraries", Jour-
nal of immunological methods, vol. 290, no. 1-2, pp. 29-49.  
Brambilla, R. & Klein, R. 1995, "Telling Axons Where to Grow: A Role for Eph Re-
ceptor Tyrosine Kinases in Guidance", Molecular and Cellular Neuroscience, vol. 
6, no. 6, pp. 487-495.  
Bratkovič , T. 2010, "Progress in phage display: evolution of the technique and its ap-
plications", Cellular and Molecular Life Sciences, vol. 67, no. 5, pp. 749-767.  
Buerk, D.G. 1995, Biosensors: Theory and Applications, Taylor & Francis.  
Campbell, M.K. & Farrell, S.O. 2012, Biochemistry, Brooks/Cole, Cengage Learning.  
Chasteen, L., Ayriss, J., Pavlik, P. & Bradbury, A.R.M. 2006, "Eliminating helper 
phage from phage display", Nucleic acids research, vol. 34, no. 21, pp. e145-e145.  
Cirino, P.C., Mayer, K.M. & Umeno, D. 2003, "Generating mutant libraries using error-
prone PCR" in Directed Evolution Library Creation Springer, pp. 3-9.  
Cooper, M.A. 2002, "Optical biosensors in drug discovery", Nat Rev Drug Discov, vol. 
1, no. 7, pp. 515-528.  
Cueto, M., Dorta, M.J., Munguía, O. & Llabrés, M. 2003, "New approach to stability 
assessment of protein solution formulations by differential scanning calorimetry", 
International journal of pharmaceutics, vol. 252, no. 1–2, pp. 159-166.  
Deisenhofer, J. 1981, "Crystallographic refinement and atomic models of a human Fc 
fragment and its complex with fragment B of protein A from Staphylococcus aure-




Desvaux, M., Dumas, E., Chafsey, I. & Hébraud, M. 2006, "Protein cell surface display 
in Gram-positive bacteria: from single protein to macromolecular protein struc-
ture", FEMS microbiology letters, vol. 256, no. 1, pp. 1-15.  
Dhillon, J.K., Drew, P.D. & Porter, A.J.R. 1999, "Bacterial surface display of an anti-
pollutant antibody fragment", Letters in applied microbiology, vol. 28, no. 5, pp. 
350-354.  
Engfeldt, T., Renberg, B., Brumer, H., Nygren, P.Å. & Eriksson Karlström, A. 2005, 
"Chemical synthesis of triple-labelled three-helix bundle binding proteins for spe-
cific fluorescent detection of unlabelled protein", ChemBioChem, vol. 6, no. 6, pp. 
1043-1050.  
Engfeldt, T., Renberg, B., Brumer, H., Nygren, P.Å. & Eriksson Karlström, A. 2005, 
"Chemical Synthesis of Triple-Labelled Three-Helix Bundle Binding Proteins for 
Specific Fluorescent Detection of Unlabelled Protein", ChemBioChem, vol. 6, no. 
6, pp. 1043-1050.  
Ewalt, K.L., Schimmel, P., Perlmann., G.E. & Manning J.M. 2014, “Protein”, Ac-
cessScience. McGraw-Hill Education. 
http://www.accessscience.com/content/protein/550200  (12 Apr.2014). 
Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, 
D., Lindqvist, E., Fant, G., Höidén-Guthenberg, I., Galli, J., Jonasson, P. & Abrahmsén, 
L. 2010, "Design of an Optimized Scaffold for Affibody Molecules", Journal of Molec-
ular Biology, vol. 398, no. 2, pp. 232-247.  
Flanagan, J.G. & Vanderhaeghen, P. 1998, " The Ephrins and Eph receptors in neural 
development”, Annual Review of Neuroscience, vol. 21, no. 1, pp. 309-345.  
Fox, B.P. & Kandpal, R.P. 2004, "Invasiveness of breast carcinoma cells and transcript 
profile: Eph receptors and ephrin ligands as molecular markers of potential diag-
nostic and prognostic application", Biochemical and biophysical research commu-
nications, vol. 318, no. 4, pp. 882-892.  
Francisco, J.A., Campbell, R., Iverson, B.L. & Georgiou, G. 1993, "Production and flu-
orescence-activated cell sorting of Escherichia coli expressing a functional anti-
body fragment on the external surface", Proceedings of the National Academy of 
Sciences, vol. 90, no. 22, pp. 10444-10448.  
Freyer, M.W. & Lewis, E.A. 2008, "Isothermal titration calorimetry: experimental de-
sign, data analysis, and probing macromolecule/ligand binding and kinetic interac-
tions", Methods in cell biology, vol. 84, pp. 79-113.  
Friedman, M., Nordberg, E., Höidén-Guthenberg, I., Brismar, H., Adams, G.P., Nilsson, 
F.Y., Carlsson, J. & Ståhl, S. 2007, "Phage display selection of Affibody molecules 
with specific binding to the extracellular domain of the epidermal growth factor re-




Gill, P., Moghadam, T.T. & Ranjbar, B. 2010, "Differential scanning calorimetry tech-
niques: applications in biology and nanoscience", Journal of biomolecular tech-
niques : JBT, vol. 21, no. 4, pp. 167-193.  
Goletz, S., Christensen, P.A., Kristensen, P., Blohm, D., Tomlinson, I., Winter, G. & 
Karsten, U. 2002, "Selection of large diversities of antiidiotypic antibody fragments 
by phage display", Journal of Molecular Biology, vol. 315, no. 5, pp. 1087-1097.  
Göstring, L., Malm, M., Höidén-Guthenberg, I., Frejd, F.Y., Ståhl, S., Löfblom, J. & 
Gedda, L. 2012, "Cellular effects of HER3-specific affibody molecules", PloS one, 
vol. 7, no. 6, pp. e40023.  
Griffiths, A.D., Williams, S.C., Hartley, O., Tomlinson, I.M., Waterhouse, P., Crosby, 
W.L., Kontermann, R.E., Jones, P.T., Low, N.M. & Allison, T.J. 1994, "Isolation 
of high affinity human antibodies directly from large synthetic repertoires", The 
EMBO journal, vol. 13, no. 14, pp. 3245-3260.  
Grimm, S. 2007. Ribosome display for selection and evolution of affibody molecules. 
Ph.D. Stockholm: KTH Royal Institute of Technology. 
Grimm, S., Yu, F. & Nygren, P. 2011, "Ribosome Display Selection of a Murine IgG1 
Fab Binding Affibody Molecule Allowing Species Selective Recovery Of Mono-
clonal Antibodies", Molecular biotechnology, vol. 48, no. 3, pp. 263-276.  
Grönwall, C. 2008, Affibody molecules for proteomic and therapeutic applications. 
Ph.D. Stockholm: KTH Royal Institute of Technology. 
Grönwall, C., Snelders, E., Palm, A.J., Eriksson, F., Herne, N. & Stahl, S. 2008, "Gen-
eration of Affibody ligands binding interleukin-2 receptor alpha/CD25", Biotech-
nology and applied biochemistry, vol. 50, no. Pt 2, pp. 97-112.  
Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S. & Herne, N. 2007, 
"Selection and characterization of Affibody ligands binding to Alzheimer amyloid 
β peptides", Journal of Biotechnology, vol. 128, no. 1, pp. 162-183.  
Gunneriusson, E., Samuelson, P., Ringdahl, J., Grönlund, H., Nygren, P. & Ståhl, S. 
1999, "Staphylococcal Surface Display of Immunoglobulin A (IgA)- and IgE-
Specific In Vitro-Selected Binding Proteins (Affibodies) Based on Staphylococcus 
aureus Protein A", Applied and Environmental Microbiology, vol. 65, no. 9, pp. 
4134-4140.  
Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H.R. & Plückthun, A. 1998, 
"Ribosome display efficiently selects and evolves high-affinity antibodies in vitro 
from immune libraries", Proceedings of the National Academy of Sciences, vol. 95, 
no. 24, pp. 14130-14135.  
Hanes, J., Schaffitzel, C., Knappik, A. & Pluckthun, A. 2000, "Picomolar affinity anti-
bodies from a fully synthetic naive library selected and evolved by ribosome dis-




Hartley, H. 1951, "Origin of the Word /`Protein/'", Nature, vol. 168, no. 4267, pp. 244-
244.  
He, M. & Khan, F. 2005, "Ribosome display: next-generation display technologies for 
production of antibodies in  vitro", Expert Review of Proteomics, vol. 2, no. 3, pp. 
421-430.  
Hedberg, P. 2003, Selection of CD4-specific Affibody® molecules to be used for human 
T lymphocyte separation. Master thesis. Uppsala: Uppsala University. 
Hoffmann, A., Bukau, B. & Kramer, G. 2010, "Structure and function of the molecular 
chaperone Trigger Factor", Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research, vol. 1803, no. 6, pp. 650-661.  
Jason-Moller, L., Murphy, M. & Bruno, J. 2001, "Overview of Biacore Systems and 
Their Applications" in Current Protocols in Protein Science John Wiley & Sons, 
Inc., .  
Johnson, C.M. 2013, "Differential scanning calorimetry as a tool for protein folding and 
stability", Archives of Biochemistry and Biophysics, vol. 531, no. 1–2, pp. 100-109.  
Jonsson, A., Dogan, J., Herne, N., Abrahmsén, L. & Nygren, P. 2008, "Engineering of a 
femtomolar affinity binding protein to human serum albumin", Protein Engineer-
ing Design and Selection, vol. 21, no. 8, pp. 515-527.  
Jonsson, A., Wållberg, H., Herne, N., Ståhl, S. & Frejd, F.Y. 2009, "Generation of tu-
mour-necrosis-factor-?-specific affibody1 molecules capable of blocking receptor 
binding in vitro", Biotechnology and applied biochemistry, vol. 54, no. 2, pp. 93-
103.  
Karlsson, R. & Fält, A. 1997, "Experimental design for kinetic analysis of protein-
protein interactions with surface plasmon resonance biosensors", Journal of immu-
nological methods, vol. 200, no. 1–2, pp. 121-133. 
Karplus, P.A., Pearson, M.A. & Hausinger, R.P. 1997, "70 years of crystalline urease: 
what have we learned?", Accounts of Chemical Research, vol. 30, no. 8, pp. 330-
337.  
Kayushin, A.L., Korosteleva, M.D., Miroshnikov, A.I., Kosch, W., Zubov, D. & Piel, 
N. 1996, "A convenient approach to the synthesis of trinucleotide phospho-
ramidites--synthons for the generation of oligonucleotide/peptide libraries", Nucle-
ic acids research, vol. 24, no. 19, pp. 3748-3755.  
Kelly, S.M., Jess, T.J. & Price, N.C. 2005, "How to study proteins by circular dichro-
ism", Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol. 1751, 
no. 2, pp. 119-139.  
Kendrew, J.C., Bodo, G., Dintzis, H.M., Parrish, R.G., Wyckoff, H. & Phillips, D.C. 
1958, "A Three-Dimensional Model of the Myoglobin Molecule Obtained by X-




Kinoshita, M., Yoshioka, Y., Okita, Y., Hashimoto, N. & Yoshimine, T. 2010, "MR 
molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-
HER-2 affibody", Contrast media & molecular imaging, vol. 5, no. 1, pp. 18-22.  
Köhler, G. & Milstein, C. 1975, "Continuous cultures of fused cells secreting antibody 
of predefined specificity", Nature, vol. 256, no. 5517, pp. 495-497.  
Kondo, A. & Ueda, M. 2004, "Yeast cell-surface display --applications of molecular 
display", Applied Microbiology and Biotechnology, vol. 64, no. 1, pp. 28-40.  
Kristensen, P. & Winter, G. 1998, "Proteolytic selection for protein folding using fila-
mentous bacteriophages", Folding & design, vol. 3, no. 5, pp. 321-328.  
Kronqvist, N., Löfblom, J., Jonsson, A., Wernérus, H. & Ståhl, S. 2008, "A novel affini-
ty protein selection system based on staphylococcal cell surface display and flow 
cytometry", Protein Engineering Design and Selection, vol. 21, no. 4, pp. 247-255.  
Kullander, K. & Klein, R. 2002, "Mechanisms and functions of eph and ephrin signal-
ling", Nature reviews. Molecular cell biology, vol. 3, no. 7, pp. 475-486.  
Lee, S.Y., Choi, J.H. & Xu, Z. 2003, "Microbial cell-surface display", Trends in bio-
technology, vol. 21, no. 1, pp. 45-52.  
Lindgren, J., Segerfeldt, P., Sholts, S.B., Gräslund, A., Karlström, A.E. & Wärmländer, 
S.K.T.S. 2013, "Engineered non-fluorescent Affibody molecules facilitate studies 
of the amyloid-beta (Aβ) peptide in monomeric form: Low pH was found to reduce 
Aβ/Cu(II) binding affinity", Journal of inorganic biochemistry, vol. 120, no. 0, pp. 
18-23.  
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S. & Frejd, F.Y. 2010, 
"Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotech-
nological applications", FEBS letters, vol. 584, no. 12, pp. 2670-2680.  
Löfblom, J., Kronqvist, N., Uhlén, M., Ståhl, S. & Wernérus, H. 2007, "Optimization of 
electroporation-mediated transformation: Staphylococcus carnosus as model organ-
ism", Journal of applied microbiology, vol. 102, no. 3, pp. 736-747.  
Lumry, R. & Eyring, H. 1954, "Conformation Changes of Proteins", The Journal of 
physical chemistry, vol. 58, no. 2, pp. 110-120.  
Lundberg, E., Höidén-Guthenberg, I., Larsson, B., Uhlén, M. & Gräslund, T. 2007, 
"Site-specifically conjugated anti-HER2 Affibody® molecules as one-step reagents 
for target expression analyses on cells and xenograft samples", Journal of immuno-
logical methods, vol. 319, no. 1–2, pp. 53-63.  
Lyakhov, I., Zielinski, R., Kuban, M., Kramer-Marek, G., Fisher, R., Chertov, O., Bin-
du, L. & Capala, J. 2010, "HER2- and EGFR-specific affiprobes: novel recombi-
nant optical probes for cell imaging", Chembiochem : a European journal of chem-




Magnusson, M.K., Henning, P., Myhre, S., Wikman, M., Uil, T.G., Friedman, M., An-
dersson, K.M., Hong, S.S., Hoeben, R.C., Habib, N.A., Stahl, S., Boulanger, P. & 
Lindholm, L. 2007, "Adenovirus 5 vector genetically re-targeted by an Affibody 
molecule with specificity for tumor antigen HER2/neu", Cancer gene therapy, vol. 
14, no. 5, pp. 468-479.  
Mesnage, S., Weber-Levy, M., Haustant, M., Mock, M. & Fouet, A. 1999, "Cell Sur-
face-Exposed Tetanus Toxin Fragment C Produced by Recombinant Bacillus an-
thracis Protects against Tetanus Toxin", Infection and immunity, vol. 67, no. 9, pp. 
4847-4850.  
Myhre, S., Henning, P., Friedman, M., Stahl, S., Lindholm, L. & Magnusson, M.K. 
2009, "Re-targeted adenovirus vectors with dual specificity; binding specificities 
conferred by two different Affibody molecules in the fiber", Gene therapy, vol. 16, 
no. 2, pp. 252-261.  
Nakada, M., Drake, K.L., Nakada, S., Niska, J.A. & Berens, M.E. 2006, "Ephrin-B3 
Ligand Promotes Glioma Invasion through Activation of Rac1", Cancer research, 
vol. 66, no. 17, pp. 8492-8500.  
Nord, K., Nilsson, J., Nilsson, B., Uhlen, M. & Nygren, P.A. 1995, "A combinatorial 
library of an alpha-helical bacterial receptor domain", Protein engineering, vol. 8, 
no. 6, pp. 601-608.  
Nord, K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M. & Nygren, P. 1996, 
"Binding proteins selected from combinatorial libraries of an alpha]-helical bacteri-
al receptor domain", Nat Biotech, vol. 15, no. 8, pp. 772-777.  
Nord, K., Gunneriusson, E., Uhlén, M. & Nygren, P.A. 2000, "Ligands selected from 
combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-
1M and Taq DNA polymerase", Journal of Biotechnology, vol. 80, no. 1, pp. 45-
54.  
Nord, O., Gustrin, A. & Nygren, P.A. 2005, "Fluorescent detection of beta-lactamase 
activity in living Escherichia coli cells via esterase supplementation", FEMS mi-
crobiology letters, vol. 242, no. 1, pp. 73-79.  
Nygren, P.A. 2008, "Alternative binding proteins: affibody binding proteins developed 
from a small three-helix bundle scaffold", The FEBS journal, vol. 275, no. 11, pp. 
2668-2676.  
Orlova, A., Magnusson, M., Eriksson, T.L., Nilsson, M., Larsson, B., Hoiden-
Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Stahl, S. & Nilsson, 
F.Y. 2006, "Tumor imaging using a picomolar affinity HER2 binding affibody 
molecule", Cancer research, vol. 66, no. 8, pp. 4339-4348.  
Orlova, A., Jonsson, A., Rosik, D., Lundqvist, H., Lindborg, M., Abrahmsen, L., 
Ekblad, C., Frejd, F.Y. & Tolmachev, V. 2013, "Site-Specific Radiometal Labeling 




Molecule–Albumin-Binding Domain Fusion Protein", Journal of Nuclear Medi-
cine, vol. 54, no. 6, pp. 961-968.  
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nils-
son, F.Y., Wennborg, A., Abrahmsén, L. & Feldwisch, J. 2007, Synthetic Affibody 
Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-
Expressing Malignant Tumors.  
Orlova, A., Tran, T., Ekblad, T., Karlström, A. & Tolmachev, V. 2010, "186Re-
maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of 
HER2-expressing tumours", European Journal of Nuclear Medicine and Molecular 
Imaging, vol. 37, no. 2, pp. 260-269.  
Pansri, P., Jaruseranee, N., Rangnoi, K., Kristensen, P. & Yamabhai, M. 2009, "A com-
pact phage display human scFv library for selection of antibodies to a wide variety 
of antigens", BMC biotechnology, vol. 9, pp. 6-6750-9-6.  
Pasquale, E.B. 1997, "The Eph family of receptors", Current opinion in cell biology, 
vol. 9, no. 5, pp. 608-615.  
Perutz, M.F., Rossmann, M.G., Cullis, A.F., Muirhead, H., Will, G. & North, A.C. 
1960, "Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. 
resolution, obtained by X-ray analysis", Nature, vol. 185, no. 4711, pp. 416-422.  
Puri, A., Kramer-Marek, G., Campbell-Massa, R., Yavlovich, A., Tele, S.C., Lee, S.B., 
Clogston, J.D., Patri, A.K., Blumenthal, R. & Capala, J. 2008, "HER2-specific af-
fibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of 
anticancer agents", Journal of Liposome Research, vol. 18, no. 4, pp. 293-307.  
Renberg, B., Nordin, J., Merca, A., Uhlén, M., Feldwisch, J., Nygren, P. & Eriksson 
Karlström, A. 2007, "Affibody Molecules in Protein Capture Microarrays: Evalua-
tion of Multidomain Ligands and Different Detection Formats", Journal of Prote-
ome Research, vol. 6, no. 1, pp. 171-179.  
Renberg, B., Nygren, P., Eklund, M. & Karlström, A.E. 2004, "Fluorescence resonance 
energy transfer-based detection of analytes using antiidiotypic affinity protein 
pairs", Analytical Biochemistry, vol. 334, no. 1, pp. 72-80.  
Roh, S., Chung, T. & Lee, B. 2011, "Overview of the characteristics of micro-and nano-
structured surface plasmon resonance sensors", Sensors, vol. 11, no. 2, pp. 1565-
1588.  
Rönnmark, J., Grönlund, H., Uhlén, M. & Nygren, P. 2002, "Human immunoglobulin A 
(IgA)-specific ligands from combinatorial engineering of protein A", European 
Journal of Biochemistry, vol. 269, no. 11, pp. 2647-2655.  
Rönnmark, J., Hansson, M., Nguyen, T., Uhlén, M., Robert, A., Ståhl, S. & Nygren, P. 
2002, "Construction and characterization of affibody-Fc chimeras produced in 





Rönnmark, J., Kampf, C., Asplund, A., Höidén-Guthenberg, I., Wester, K., Pontén, F., 
Uhlén, M. & Nygren, P. 2003, "Affibody-β-galactosidase immunoconjugates pro-
duced as soluble fusion proteins in the Escherichia coli cytosol", Journal of immu-
nological methods, vol. 281, no. 1–2, pp. 149-160.  
Samuelson, P., Hansson, M., Ahlborg, N., Andréoni, C., Götz, F., Bächi, T., Nguyen, 
T.N., Binz, H., Uhlén, M. & Ståhl, S. 1995, "Cell surface display of recombinant 
proteins on Staphylococcus carnosus.", Journal of Bacteriology, vol. 177, no. 6, pp. 
1470-1476.  
Sandstrom, K., Xu, Z., Forsberg, G. & Nygren, P.A. 2003, "Inhibition of the CD28-
CD80 co-stimulation signal by a CD28-binding affibody ligand developed by com-
binatorial protein engineering", Protein engineering, vol. 16, no. 9, pp. 691-697.  
Sanger, F. & Tuppy, H. 1951, "The amino-acid sequence in the phenylalanyl chain of 
insulin. I. The identification of lower peptides from partial hydrolysates", The Bio-
chemical journal, vol. 49, no. 4, pp. 463-481.  
Sawyer, N., Speltz, E.B. & Regan, L. 2013, "NextGen protein design", Biochemical 
Society transactions, vol. 41, no. 5, pp. 1131-1136.  
Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., 
Wong, A., Lee, C.V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G.D., Prell, 
R.A., Danilenko, D.M., Franke, Y., Stephan, J.P., Hwang, J., Wu, Y., Bostrom, J., 
Sliwkowski, M.X., Fuh, G. & Eigenbrot, C. 2011, "A two-in-one antibody against 
HER3 and EGFR has superior inhibitory activity compared with monospecific an-
tibodies", Cancer cell, vol. 20, no. 4, pp. 472-486. 
Schneewind, O., Mihaylova-Petkov, D. & Model, P. 1993, "Cell wall sorting signals in 
surface proteins of gram-positive bacteria", The EMBO journal, vol. 12, no. 12, pp. 
4803-4811.  
Scopes, R.K. 2001, "Enzyme Activity and Assays" in eLS John Wiley & Sons, Ltd, .  
Smith, B., Lyakhov, I., Loomis, K., Needle, D., Baxa, U., Yavlovich, A., Capala, J., 
Blumenthal, R. & Puri, A. 2011, "Hyperthermia-triggered intracellular delivery of 
anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-
conjugated thermosensitive liposomes (HER2+ affisomes)", Journal of Controlled 
Release, vol. 153, no. 2, pp. 187-194.  
Smith, G. 1985, "Filamentous fusion phage: novel expression vectors that display 
cloned antigens on the virion surface", Science, vol. 228, no. 4705, pp. 1315-1317.  
Stahl, S., Kaminskyy, V.O., Efazat, G., Hyrslova Vaculova, A., Rodriguez-Nieto, S., 
Moshfegh, A., Lewensohn, R., Viktorsson, K. & Zhivotovsky, B. 2013, "Inhibition 
of Ephrin B3-mediated survival signaling contributes to increased cell death re-
sponse of non-small cell lung carcinoma cells after combined treatment with ioniz-




Steffen, A., Wikman, M., Tolmachev, V., Adams, G.P., Nilsson, F.Y., Ståhl, S. & 
Carlsson, J. 2005, "In vitro characterization of a bivalent anti-HER-2 affibody with 
potential for radionuclide-based diagnostics", Cancer biotherapy & radiopharma-
ceuticals, vol. 20, no. 3, pp. 239-248.  
Stentebjerg-Olesen, B., Pallesen, L., Jensen, L.B., Christiansen, G. & Klemm, P. 1997, 
"Authentic display of a cholera toxin epitope by chimeric type 1 fimbriae: effects 
of insert position and host background", Microbiology, vol. 143, no. 6, pp. 2027-
2038.  
Thomas, W.D. & Smith, G.P. 2010, "The case for trypsin release of affinity-selected 
phages", BioTechniques, vol. 49, no. 3, pp. 651-654.  
Tolmachev, V., Nilsson, F.Y., Widstrom, C., Andersson, K., Rosik, D., Gedda, L., 
Wennborg, A. & Orlova, A. 2006, "111In-benzyl-DTPA-ZHER2:342, an affibody-
based conjugate for in vivo imaging of HER2 expression in malignant tumors", 
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 
vol. 47, no. 5, pp. 846-853.  
Tolmachev, V., Velikyan, I., Sandstrom, M. & Orlova, A. 2010, "A HER2-binding Af-
fibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison 
with the 111In-labelled analogue", European journal of nuclear medicine and mo-
lecular imaging, vol. 37, no. 7, pp. 1356-1367.  
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sand-
ström, M., Rosik, D., Carlsson, J., Lundqvist, H., Wennborg, A. & Nilsson, F.Y. 
2007, Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-
Labeled HER2-Specific Affibody Molecule.  
Van der Vaart, J.M., te Biesebeke, R., Chapman, J.W., Toschka, H.Y., Klis, F.M. & 
Verrips, C.T. 1997, "Comparison of cell wall proteins of Saccharomyces cerevisiae 
as anchors for cell surface expression of heterologous proteins.", Applied and Envi-
ronmental Microbiology, vol. 63, no. 2, pp. 615-620.  
Virnekas, B., Ge, L., Pluckthun, A., Schneider, K.C., Wellnhofer, G. & Moroney, S.E. 
1994, "Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed 
oligonucleotides for random mutagenesis", Nucleic acids research, vol. 22, no. 25, 
pp. 5600-5607.  
Wallberg, H. & Orlova, A. 2008, "Slow internalization of anti-HER2 synthetic affibody 
monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled 
tracers", Cancer biotherapy & radiopharmaceuticals, vol. 23, no. 4, pp. 435-442.  
Wang, S.C., Zhang, L., Hortobagyi, G.N. & Hung, M.C. 2001, "Targeting HER2: recent 
developments and future directions for breast cancer patients", Seminars in oncolo-
gy, vol. 28, no. 6 Suppl 18, pp. 21-29.  
Westerlund-Wikström, B., Tanskanen, J., Virkola, R., Hacker, J., Lindberg, M., Skur-




sions to Escherichia coli flagellin.", Protein engineering, vol. 10, no. 11, pp. 1319-
1326.  
Winter, G., Fersht, A.R., Wilkinson, A.J., Zoller, M. & Smith, M. 1982, "Redesigning 
enzyme structure by site-directed mutagenesis: tyrosyl tRNA synthetase and ATP 
binding", Nature, vol. 299, no. 5885, pp. 756-758.  
Xu, Z. & Lee, S.Y. 1999, "Display of Polyhistidine Peptides on the Escherichia coli 
Cell Surface by Using Outer Membrane Protein C as an Anchoring Motif", Applied 
and Environmental Microbiology, vol. 65, no. 11, pp. 5142-5147.  
Zahnd, C., Amstutz, P. & Pluckthun, A. 2007, "Ribosome display: selecting and evolv-
ing proteins in vitro that specifically bind to a target", Nat Meth, vol. 4, no. 3, pp. 
269-279.  
Zielinski, R., Lyakhov, I., Jacobs, A., Chertov, O., Kramer-Marek, G., Francella, N., 
Stephen, A., Fisher, R., Blumenthal, R. & Capala, J. 2009, "Affitoxin--a novel re-
combinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive 













Trinuclotiders (Trimers) used in Tri-121-mer 




























Peptide sequence of protein 3 
AETVE SCLAK PHTEN SFTNV WKDDK TLDRY ANYEG CLWNA TGVVV 
CTGDE TQCYG TWVPI GLAIP ENEGG GSEGG GSEGG GSEGG GTKPP EYGDT 
PIPGY TYINP LDGTY PPGTE QNPAN PNPSL EESQP LNTFM FQNNR FRNRQ 
GALTV YTGTV TQGTD PVKTY YQYTP VSSKA MYDAY WNGKF RDCAF 
HSGFN EDPFV CEYQG QSSDL PQPPV NAGGG SGGGS GGGSE GGGSE GGGSE 
GGGSE GGGSG GGSGS GDFDY EKMAN ANKGA MTENA DENAL QSDAK 
GKLDS VATDY GAAID GFIGD VSGLA NGNGA TGDFA GSNSQ MAQVG 
DGDNS PLMNN FRQYL PSLPQ SVECR PFVFS AGKPY EFSID CDKIN LFRGV 
FAFLL YVATF MYVFS TFANI LRNKE S  
 
 
 
 
 
